Paid Clinical Trials Paid Clinical Trials > Browse Categories > Medications / Interventions > Aa > Antimetabolites Antineoplastic

Antimetabolites Antineoplastic

Antimetabolites Antineoplastic

All Categories Medications / Interventions » Aa » Antimetabolites Antineoplastic


  • Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

    Conditions:   Myeloid Malignancy;   Bone Marrow Failure Syndrome;   Transfusion-dependent Red Blood Cell (RBC) Defect;   Congenital Immunodeficiency;   Metabolic Disease;   Severe Immune Dysregulation
    Interventions:   Drug: Alemtuzumab;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine
    Sponsors:   University of California, San Francisco;   Christopher Dvorak
    Not yet recruiting - verified May 2012
  • Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

    Condition:   Solid Tumors
    Interventions:   Drug: Iniparib (SAR240550/BSI-201);   Drug: Carboplatin;   Drug: Doxorubicin HCL liposome injection;   Drug: Gemcitabine;   Drug: Irinotecan;   Drug: Paclitaxel;   Drug: Topotecan
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
    Recruiting - verified May 2012
  • A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

    Condition:   Sarcoma
    Interventions:   Drug: Gemcitabine and Pazopanib;   Drug: Gemcitabine and Docetaxel
    Sponsors:   Medical University of South Carolina;   Medical University of South Carolina;   GlaxoSmithKline
    Not yet recruiting - verified May 2012
  • Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor NK Cells for Treatment of High Risk Myelodysplastic Syndromes

    Condition:   Myelodysplastic Syndrome
    Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Biological: Interleukin-2;   Other: Natural killer (NK) cells
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified May 2012
  • Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

    Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Eribulin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Eisai Inc.
    Not yet recruiting - verified May 2012
  • Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified May 2012
  • Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

    Condition:   Bladder Cancer
    Intervention:   Drug: Gemcitabine and Cisplatin (DD GC)
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified April 2012
  • 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: VX-509;   Drug: VX-509 matching placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
    Recruiting - verified May 2012
  • Personalized Consolidation Therapy Based on Leukemia Stem Cell Behavior

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine consolidation;   Drug: Cytarabine vs BMT
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified May 2012
  • Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

    Conditions:   Metastatic Cancer;   Melanoma
    Interventions:   Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

    Conditions:   Hepatitis C;   Liver Transplant Recipient
    Interventions:   Drug: Peginterferon alfa-2a;   Drug: Ribavirin;   Drug: telaprevir
    Sponsors:   University of Chicago;   University of Chicago
    Recruiting - verified May 2012
  • FOLFIRINOX + RT for Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: FOLFIRINOX;   Drug: Capecitabine;   Radiation: Proton Radiation;   Procedure: Surgery
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2012
  • Treating Cancer With Anti-mesothelin Modified Lymphocytes

    Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

    Conditions:   Liver Cancer;   Pancreatic Cancer
    Interventions:   Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin);   Device: TheraSpheres
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Nordion (Canada) Inc.
    Recruiting - verified April 2012
  • Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

    Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity
    Interventions:   Radiation: intensity-modulated radiation therapy;   Procedure: quality-of-life assessment;   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry;   Other: immunohistochemistry staining method;   Genetic: protein expression analysis
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

    Condition:   Gastric Carcinoma
    Interventions:   Drug: Tesetaxel;   Drug: Placebo;   Drug: Capecitabine
    Sponsors:   Genta Incorporated;   Genta Incorporated
    Recruiting - verified April 2012
  • Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

    Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Crohn's Allogeneic Transplant Study

    Condition:   Crohn's Disease
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: mycophenolic acid enteric coated;   Drug: tacrolimus;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Drug: fludarabine phosphate;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified April 2012
  • Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: tosedostat;   Drug: cytarabine;   Drug: decitabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Induction Chemotherapy With Paclitaxel, Cisplatin, and Fluorouracil (ACF) Followed by Chemoradiation Therapy for Advanced Head and Neck Cancer

    Condition:   Head and Neck Neoplasms
    Interventions:   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Chemoradiation;   Radiation: Chemoradiation;   Procedure: Quality-of-life assessment
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Not yet recruiting - verified March 2012
  • A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

    Conditions:   Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.;   Seattle Genetics, Inc.
    Recruiting - verified May 2012
  • A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

    Condition:   Lymphoma, Solid Tumour
    Interventions:   Drug: GDC-0575;   Drug: gemcitabine
    Sponsors:   Genentech;   Genentech
    Recruiting - verified April 2012
  • Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: 5-FU;   Drug: Gemcitabine;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Not yet recruiting - verified March 2012
  • STA9090: Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

    Conditions:   Pancreatic Cancer;   Rectal Cancer
    Intervention:   Drug: capecitabine +ganetespib
    Sponsors:   Emory University;   Emory University;   Synta Pharmaceuticals Corp.
    Not yet recruiting - verified March 2012
  • Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

    Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: Smac mimetic TL32711;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified April 2012
  • Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Condition:   High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Ofatumumab;   Drug: Etoposide;   Drug: Cytarabine
    Sponsors:   University of California, San Francisco;   C. Babis Andreadis;   University of California, San Francisco;   GlaxoSmithKline
    Not yet recruiting - verified March 2012
  • Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

    Condition:   Cervical Carcinoma
    Interventions:   Radiation: Intensity Modulated Radiation Therapy (IMRT);   Drug: Cisplatin;   Drug: Gemcitabine
    Sponsors:   University of California, San Diego;   University of California, San Diego
    Recruiting - verified March 2012
  • Escape II Myocardium

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Triple Therapy;   Drug: TNF inhibitors
    Sponsors:   Columbia University;   Columbia University;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting - verified March 2012
  • Afatinib With CT and RT for EGFR-Mutant NSCLC

    Condition:   Lung Cancer
    Interventions:   Drug: Afatinib;   Radiation: Radiation;   Drug: Cisplatin;   Drug: Pemetrexed;   Procedure: Surgery
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
    Not yet recruiting - verified March 2012
  • Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

    Condition:   Advanced Cancers
    Interventions:   Drug: Crizotinib (Xalkori);   Drug: Pazopanib;   Drug: Pemetrexed
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

    Conditions:   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
    Interventions:   Drug: CC-223;   Drug: Erlotinib;   Drug: Oral azacitidine
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified April 2012
  • Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

    Condition:   Multiple Myeloma
    Interventions:   Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan);   Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan);   Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12);   Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
    Sponsors:   University of Iowa;   University of Iowa;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

    Condition:   Leukemia
    Interventions:   Drug: Azacytidine;   Drug: GM-CSF
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure Due to Acetaminophen

    Conditions:   Acute Liver Failure;   Acute Liver Injury
    Intervention:   Drug: Ornithine phenylacetate
    Sponsors:   University of Texas Southwestern Medical Center;   William Lee;   Medical University of South Carolina;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Ocera Therapeutics
    Not yet recruiting - verified March 2012
  • AMG 386 With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

    Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Biological: trebananib;   Drug: cytarabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified March 2012
  • FLT-PET Imaging for MDS

    Conditions:   AML;   MDS
    Intervention:   Procedure: FLT-PET scans
    Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
    Not yet recruiting - verified February 2012
  • High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Other: pharmacological study;   Drug: tacrolimus;   Drug: sirolimus;   Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: bortezomib;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified March 2012
  • Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Conditions:   Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: bendamustine hydrochloride
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center
    Recruiting - verified February 2012
  • Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma

    Conditions:   Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Hemangioendothelioma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Hemangiopericytoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: pazopanib hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI);   GlaxoSmithKline
    Recruiting - verified March 2012
  • A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: PF-05280586;   Biological: MabThera;   Biological: Rituxan
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified April 2012
  • Atorvastatin Calcium-Treated Donor Peripheral Blood Stem Cell Transplant in Preventing Severe Graft-Versus-Host Disease in Patients With Hematological Malignancies

    Conditions:   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: atorvastatin calcium;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2012
  • Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease

    Conditions:   Actinic Keratosis;   Solid Organ Transplant With Actinic Keratosis
    Intervention:   Drug: 5-Fluorouracil
    Sponsors:   The Cleveland Clinic;   The Cleveland Clinic;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

    Condition:   Urothelial Carcinoma
    Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Ipilimumab
    Sponsors:   Hoosier Oncology Group;   Hoosier Oncology Group;   Bristol-Myers Squibb
    Recruiting - verified March 2012
  • Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

    Conditions:   Metastatic Pancreatic Cancer;   ERCC1
    Intervention:   Drug: gemcitabine and oxaliplatin
    Sponsors:   University of Hawaii;   University of Hawaii
    Recruiting - verified January 2012
  • Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

    Conditions:   Cholangiocarcinoma;   Liver Neoplasms
    Interventions:   Drug: floxuridine, dexamethasone;   Drug: floxuridine, dexamethasone, gemcitabine hydrochloride;   Drug: floxuridine, dexamethasone, gemcitabine hydrochloride, oxaliplatin
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified May 2012
  • Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

    Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
    Interventions:   Drug: oral azacitidine;   Drug: oral azacitidine
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified April 2012
  • Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

    Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF;   Procedure: Low Dose Donor T-Cells;   Procedure: High Dose Donor T-Cells
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Certolizumab Pegol + Methotrexate (MTX);   Biological: Placebo + Methotrexate (MTX)
    Sponsors:   UCB, Inc.;   UCB, Inc.
    Recruiting - verified May 2012
  • Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

    Conditions:   Pancreatic Neoplasms;   Pancreatic Cancer
    Intervention:   Drug: Gemcitabine with escalating ascorbic acid
    Sponsors:   University of Iowa;   University of Iowa;   Susan L Bader Foundation of Hope;   The Holden Comprehensive Cancer Center;   The National Cancer Institute (NCI)
    Not yet recruiting - verified May 2012
  • Study of Vitamin D in Untreated Metastatic Colorectal Cancer

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: FOLFOX + bevacizumab;   Dietary Supplement: Vitamin D;   Dietary Supplement: Vitamin D
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
    Recruiting - verified April 2012
  • Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

    Condition:   Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

    Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Burkitts Leukemia/Lymphoma;   Chronic Myelogenous Leukemia
    Interventions:   Drug: CLAG-M;   Drug: CLAG-M
    Sponsors:   New York Medical College;   New York Medical College
    Recruiting - verified January 2012
  • Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

    Conditions:   Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
    Interventions:   Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
    Sponsors:   Stanford University;   Stanford University;   National Cancer Institute (NCI)
    Not yet recruiting - verified January 2012
  • A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

    Conditions:   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Cancer;   Metastatic Pancreatic Cancer
    Intervention:   Drug: 90Y-hPAM4
    Sponsors:   Immunomedics, Inc.;   Immunomedics, Inc.
    Recruiting - verified May 2012
  • Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

    Condition:   Leukemia
    Interventions:   Behavioral: compliance monitoring;   Behavioral: telephone-based intervention;   Drug: mercaptopurine;   Other: computer-assisted intervention;   Other: counseling intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: standard follow-up care
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer

    Conditions:   Advanced Adenocarcinoma;   Metastatic Adenocarcinoma
    Interventions:   Drug: Hydroxychloroquine (HCQ);   Drug: Gemcitabine
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified January 2012
  • 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
    Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Certolizumab pegol + Methotrexate (CZP + MTX);   Biological: Adalimumab + Methotrexate (ADA + MTX)
    Sponsors:   UCB, Inc.;   UCB, Inc.
    Recruiting - verified May 2012
  • Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma

    Conditions:   Central Nervous System Malignancies;   Ependymoma
    Intervention:   Drug: 5-fluorouracil
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified December 2011
  • Phase I/II - Dasatinib and Decitabine

    Condition:   Leukemia
    Interventions:   Drug: Dasatinib;   Drug: Decitabine;   Drug: Decitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Not yet recruiting - verified April 2012
  • PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer

    Condition:   Colorectal Cancer
    Intervention:   Drug: PF-0332991, 5-FU, oxaliplatin
    Sponsors:   Georgetown University;   Georgetown University;   Pfizer
    Recruiting - verified December 2011
  • A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

    Conditions:   Cancer;   Neoplasms;   Tumors
    Intervention:   Drug: OSI-906 and Pemetrexed
    Sponsors:   Emory University;   Emory University;   OSI Pharmaceuticals
    Not yet recruiting - verified March 2012
  • A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: RO5490258;   Drug: bevacizumab [Avastin];   Drug: pemetrexed;   Drug: Placebo;   Drug: cisplatin/carboplatin;   Drug: paclitaxel
    Sponsors:   Genentech;   Genentech
    Not yet recruiting - verified January 2012
  • Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

    Conditions:   Mestatic Melanoma;   Skin Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Study of MM-398 Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

    Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: MM-398;   Drug: 5 Fluorouracil;   Drug: Leucovorin
    Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
    Recruiting - verified April 2012
  • Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Conditions:   Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: cytarabine;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: methotrexate
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Comprehensive Cancer Network
    Recruiting - verified April 2012
  • Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

    Conditions:   Solid Tumors;   Bladder Cancer
    Interventions:   Drug: Gemcitabine + Cisplatin + Dovitinib;   Drug: Gemcitabine + Carboplatin + Dovitinib
    Sponsors:   Mount Sinai School of Medicine;   Matthew Galsky;   Novartis
    Recruiting - verified March 2012
  • Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: 111In Ibritumumab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumumabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Not yet recruiting - verified May 2012
  • Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: atorvastatin;   Drug: Tacrolimus;   Drug: methotrexate
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center
    Recruiting - verified January 2012
  • ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

    Condition:   Metastatic Pancreatic Cancer
    Intervention:   Drug: Veliparib and 5-FU and Oxaliplatin and Leucovorin
    Sponsors:   Georgetown University;   Georgetown University;   Abbott
    Recruiting - verified December 2011
  • Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

    Condition:   Pancreatic Cancer
    Intervention:   Drug: LDE225+gemcitabine
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Intervention:   Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
    Recruiting - verified December 2011
  • Patient Factors Impacting Adherence to Oral Chemotherapy

    Conditions:   Breast Cancer;   Gastrointestinal Cancer
    Intervention:   Behavioral: questionnaire and interview
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2012
  • A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

    Conditions:   Acute Lymphoblastic Leukemia;   Precursor B-Cell Lymphoblastic Leukemia;   Precursor T-Cell Lymphoblastic Leukemia
    Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Methotrexate
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
    Recruiting - verified March 2012
  • Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

    Conditions:   Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
    Interventions:   Drug: Alisertib;   Drug: Pralatrexate;   Drug: Romidepsin;   Drug: Gemcitabine
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2012
  • Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

    Conditions:   HIV Infections;   Hepatitis C
    Interventions:   Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified May 2012
  • Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Malignant Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Lymphocytic Leukemia;   Myeloproliferative Disorder;   Polycythemia Vera;   Myelofibrosis;   Aplastic Anemia
    Interventions:   Drug: fludarabine/busulfan;   Drug: fludarabine/ melphalan
    Sponsors:   University of Illinois;   University of Illinois
    Recruiting - verified September 2011
  • Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors

    Condition:   Relapsed or Refractory Solid Tumors
    Interventions:   Drug: Oral azacitidine plus Abraxane;   Drug: Carboplatin;   Drug: Abraxane
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified April 2012
  • Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

    Condition:   Stage IV Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: FOLFIRINOX;   Genetic: Immunohistochemistry (IHC) Analysis;   Drug: Metformin
    Sponsors:   Pancreatic Cancer Research Team;   Pancreatic Cancer Research Team
    Recruiting - verified March 2012
  • Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Hodgkins Disease;   Non-Hodgkins Lymphoma;   Aplastic Anemia;   Multiple Myeloma;   Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Clofarabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine
    Sponsors:   Texas Oncology Cancer Center;   Texas Oncology Cancer Center
    Recruiting - verified December 2011
  • Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

    Condition:   Recurrent Adult Hodgkin Lymphoma
    Interventions:   Biological: basiliximab;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: basiliximab;   Biological: basiliximab
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2011
  • ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: G-CSF;   Drug: Cytarabine;   Drug: Fludarabine;   Biological: Donor Natural Killer (NK) cells;   Biological: ALT-801
    Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    Conditions:   Disorder Related to Bone Marrow Transplantation;   Leukemia;   Transplantation Infection
    Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

    Condition:   Lung Cancer - Non Small Cell
    Interventions:   Biological: Ipilimumab;   Biological: Pemetrexed
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Not yet recruiting - verified February 2012
  • A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

    Condition:   Pancreatic Cancer
    Interventions:   Drug: GS-6624;   Drug: GS-6624;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: GS-6624
    Sponsors:   Gilead Sciences;   Gilead Sciences
    Recruiting - verified March 2012
  • Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer Metastatic
    Intervention:   Drug: Chemotherapy
    Sponsors:   University of Florida;   University of Florida
    Recruiting - verified February 2012
  • Cord Blood Fucosylation

    Conditions:   Blood And Marrow Transplantation;   Leukemia;   Lymphoma;   Transplantation Infection;   Transplantation, Bone Marrow
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Procedure: Cord Blood Infusion;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Not yet recruiting - verified April 2012
  • Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Chemotherapy;   Drug: Chemotherapy and ChemoRadiotherapy
    Sponsors:   University of Florida;   University of Florida
    Recruiting - verified February 2012
  • A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

    Condition:   Colorectal Cancer
    Interventions:   Drug: Axitinib;   Drug: Bevacizumab;   Drug: 5-FU;   Drug: 5-FU;   Drug: Leucovorin;   Drug: Oxaliplatin
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Pfizer
    Recruiting - verified January 2012
  • Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

    Conditions:   Hodgkin Disease;   Hodgkin Lymphoma
    Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Drug: Yttrium-Daclizumab (CHX-A Daclizumab);   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Ca(2+)-DTPA
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

    Condition:   Acute Myelogenous Leukemia
    Intervention:   Biological: Vaccine
    Sponsors:   Penn State University;   Penn State University
    Recruiting - verified November 2011
  • T-Cell Depleted Double UCB for Refractory AML

    Conditions:   Acute Myelogenous Leukemia;   Refractory Acute Myelogenous Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Radiation: Total body irradiation;   Drug: Cyclophosphamide;   Drug: Levetiracetam;   Drug: Busulfan;   Biological: Umbilical Cord Blood Transplantation;   Biological: Interleukin-2
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

    Condition:   Colorectal Cancer, Metastatic
    Interventions:   Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay;   Other: Standard of care
    Sponsors:   Myriad Genetic Laboratories, Inc.;   Myriad Genetic Laboratories, Inc.
    Recruiting - verified February 2012
  • Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

    Condition:   Hepatitis C, Genotype 1
    Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified April 2012
  • Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

    Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
    Intervention:   Biological: Toca 511
    Sponsors:   Tocagen Inc.;   Tocagen Inc.
    Recruiting - verified January 2012
  • Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

    Conditions:   Acute Myeloid Leukemia;   Advanced Myelodysplastic Syndrome
    Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsors:   University of California, San Francisco;   C. Babis Andreadis;   University of California, San Francisco;   Novartis
    Recruiting - verified March 2012
  • Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Taxotere;   Drug: Xeloda;   Drug: Cisplatin
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified December 2011
  • Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

    Condition:   Leukemia
    Interventions:   Drug: Azacitidine (AZA);   Drug: Tyrosine kinase inhibitor (TKI);   Drug: Azacitidine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Not yet recruiting - verified April 2012
  • Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Radiation: Proton Therapy;   Drug: Gemcitabine
    Sponsors:   University of Florida;   University of Florida
    Recruiting - verified March 2012
  • Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

    Condition:   Adenocarcinoma Pancreas
    Interventions:   Other: Gemcitabine;   Drug: CP-870,893
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Not yet recruiting - verified March 2012
  • Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

    Conditions:   Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
    Interventions:   Biological: ipilimumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Northwestern University;   Northwestern University;   Robert H. Lurie Cancer Center
    Not yet recruiting - verified November 2011
  • A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

    Conditions:   Locally Advance Breast Cancer (LABC);   Metastatic Breast Cancer (MBC)
    Interventions:   Drug: BEZ235 + Trastuzumab Phase l/Phase ll);   Drug: Lapatinib + Capecitabine (Phase II)
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • Study of ABT-700 in Subjects With Advanced Solid Tumors

    Condition:   Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
    Interventions:   Drug: ABT-700;   Drug: ABT-700 plus erlotinib;   Drug: ABT-700 plus Oxaliplatin and Capecitabine
    Sponsors:   Abbott;   Abbott
    Recruiting - verified March 2012
  • Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

    Condition:   Metastatic Pancreatic Cancer
    Interventions:   Drug: Abraxane ( Nab-paclitaxel);   Drug: Abraxane ( Nab-paclitaxel);   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: ODSH ( 2-O, 3-O Desulfated Heparin);   Drug: ODSH ( 2-O, 3-O Desulfated Heparin);   Drug: Abraxane ( nab-paclitaxel);   Drug: Gemcitabine
    Sponsors:   ParinGenix;   ParinGenix;   TGen Drug Development Services
    Recruiting - verified April 2012
  • A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer (NSCLC)
    Interventions:   Drug: Eribulin;   Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
    Sponsors:   Eisai Inc.;   Eisai Inc.
    Recruiting - verified April 2012
  • In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease

    Condition:   Graft Versus Host Disease
    Interventions:   Drug: Cyclophospahmide and Sirolimus;   Drug: Low dose IL-2, Cyclophosphamide and Sirolimus;   Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
    Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
    Recruiting - verified October 2011
  • A Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib

    Condition:   Multiple Myeloma
    Intervention:   Drug: Fludarabine monophosphate, melphalan, Bortezomib
    Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
    Recruiting - verified October 2011
  • Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

    Condition:   Stage IV Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: PEGPH20+ gemcitabine
    Sponsors:   Halozyme Therapeutics;   Halozyme Therapeutics
    Recruiting - verified March 2012
  • A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

    Condition:   Neoplasm Malignant
    Interventions:   Drug: Iniparib (SAR240550-BSI-201);   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Placlitaxel;   Drug: Pegylated liposomal doxorubicin
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
    Recruiting - verified April 2012
  • Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM2)

    Condition:   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: MK-8242;   Drug: MK-8242;   Drug: cytarabine
    Sponsors:   Schering-Plough;   Schering-Plough
    Recruiting - verified April 2012
  • A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

    Condition:   Gastric Cancer
    Interventions:   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: capecitabine;   Drug: cisplatin
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified April 2012
  • A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young TIL
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • White Blood Cells With Anti-EGFR-III for Malignant Gliomas

    Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
    Interventions:   Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

    Condition:   Intercritical Gout
    Interventions:   Drug: Colchicine;   Drug: Placebo;   Drug: Allopurinol
    Sponsors:   Regeneron Pharmaceuticals;   Regeneron Pharmaceuticals
    Recruiting - verified April 2012
  • A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

    Conditions:   Urologic Neoplasms;   Metastatic Bladder Cancer;   Urinary Tract Neoplasms
    Interventions:   Drug: OGX-427 600 mg;   Drug: OGX-427 1000 mg;   Drug: Placebo
    Sponsors:   OncoGenex Technologies;   OncoGenex Technologies;   OncoGenex Pharmaceuticals;   PRA International
    Recruiting - verified May 2012
  • Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

    Condition:   Solid Tumors
    Interventions:   Drug: MM-121 (SAR256212) plus Gemcitabine;   Drug: MM-121 (SAR256212) plus Carboplatin;   Drug: MM-121 (SAR256212) plus Pemetrexed;   Drug: MM-121 (SAR256212) plus Cabazitaxel
    Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis US, Inc.
    Recruiting - verified January 2012
  • Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

    Condition:   Hepatitis C
    Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Placebo matching BMS-790052;   Drug: Pegylated-interferon alfa 2a;   Drug: Pegylated-interferon alfa 2a;   Drug: Ribavirin;   Drug: Ribavirin
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified December 2011
  • SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

    Condition:   Mesothelioma
    Interventions:   Drug: SS1P;   Drug: Pemetrexed;   Drug: Cisplatin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

    Condition:   Unspecified Adult Solid Tumor
    Interventions:   Drug: sorafenib tosylate;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Procedure: biopsy
    Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

    Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Clofarabine;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified December 2011
  • Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

    Condition:   Lung Cancer
    Interventions:   Drug: pemetrexed plus cisplatin;   Drug: vinorelbine and docetaxel
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Eli Lilly and Company
    Recruiting - verified January 2012
  • Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

    Conditions:   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
    Interventions:   Drug: Folfirinox;   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsors:   Emory University;   Emory University
    Recruiting - verified April 2012
  • Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

    Conditions:   Hepatitis;   HIV/AIDS
    Interventions:   Drug: Boceprevir;   Drug: Peg-Interferon-alfa 2B;   Drug: Ribavirin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified August 2011
  • Gemcitabine, Cisplatin, and Lenalidomide for Bladder Cancer

    Conditions:   Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Urethral Neoplasms
    Interventions:   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Gemcitabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Directly Observed Hepatitis C Treatment in Methadone Clinics

    Conditions:   Hepatitis C;   Medication Adherence
    Interventions:   Other: enhanced DOT (both pegylated interferon alfa-2a and ribavirin);   Other: standard DOT (PEG-DOT control arm)
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University;   National Institute on Drug Abuse (NIDA)
    Recruiting - verified September 2011
  • Azacitidine + Lenalidomide Combo in the Elderly Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS)

    Conditions:   Leukemia;   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS)
    Interventions:   Drug: Azacitidine;   Drug: Lenalidomide
    Sponsors:   Stanford University;   Stanford University;   Celgene Corporation
    Recruiting - verified September 2011
  • Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

    Conditions:   Estrogen Receptor Positive Tumor;   Breast Cancer
    Intervention:   Drug: E7389 (eribulin mesylate) and capecitabine
    Sponsors:   Eisai Inc.;   Eisai Inc.
    Recruiting - verified April 2012
  • Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease

    Condition:   Leptomeningeal Metastases
    Interventions:   Other: pharmacological study;   Drug: methotrexate
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: BMS-936558 (Anti-PD1);   Drug: BMS-936558 (Anti-PD1);   Drug: BMS-936558 (Anti-PD1);   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
    Recruiting - verified February 2012
  • Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

    Condition:   Neoplasms
    Interventions:   Drug: Gemcitabine;   Drug: BAY80-6946;   Drug: Cisplatin;   Drug: NaCl;   Drug: BAY80-6964 fixed dose
    Sponsors:   Bayer;   Bayer
    Recruiting - verified May 2012
  • Phase I Trial of Combination of FOLFIRI and SOM 230

    Condition:   Gastrointestinal Tumor
    Interventions:   Drug: SOM230C LAR;   Drug: FOLFIRI Infusion
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Novartis
    Recruiting - verified February 2012
  • Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

    Conditions:   Pancreatic Neoplasms;   Cholangiocarcinoma
    Intervention:   Drug: Gemcitabine with TheraSphere
    Sponsors:   Emory University;   Hyun Kevin Kim;   Emory University
    Recruiting - verified April 2012
  • Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

    Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
    Recruiting - verified May 2012
  • Study of Ruxolitinib in Pancreatic Cancer Patients

    Condition:   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: Number 1 - Capecitabine and ruxolitinib;   Drug: Number 2 - Capecitabine and placebo
    Sponsors:   Incyte Corporation;   Incyte Corporation
    Recruiting - verified May 2012
  • Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: bortezomib;   Drug: decitabine
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

    Condition:   Lymphoma
    Interventions:   Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Rituximab;   Drug: G-CSF;   Drug: Palifermin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

    Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified April 2012
  • Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

    Conditions:   Colorectal Cancer;   Cancer of Pancreas;   Pancreatic Neoplasm;   Malignant Neoplasm of Large Intestine;   Malignant Tumor of Colon;   Colon Carcinoma;   Cancer of Colon;   Pancreatic Cancer
    Interventions:   Drug: FOLFOX6;   Biological: EGFRBi armed ATC Infusions
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute
    Recruiting - verified September 2011
  • History of the KSHV Inflammatory Cytokine Syndrome (KICS)

    Conditions:   KSHV Inflammatory Cytokine Syndrome (KICS);   KSHV;   HHV-8
    Interventions:   Drug: Zidovudine/Valgancyclovir;   Drug: Rituximab/Liposoma Doxorubicin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

    Conditions:   Sarcoma;   Leiomyosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Fibrous;   Histiocytoma/Undifferentiated Pleomorphic Sarcoma
    Intervention:   Drug: Gemcitabine and Docetaxel in Combination with Pazopanib
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   National Comprehensive Cancer Network
    Recruiting - verified April 2012
  • Systemic Therapies for Pediatric Atopic Dermatitis

    Condition:   Dermatitis, Atopic
    Intervention:  
    Sponsors:   Northwestern University;   Northwestern University;   University of California, San Diego
    Recruiting - verified December 2011
  • OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer, Metastatic
    Interventions:   Drug: Gemcitabine, Erlotinib, OSI-906;   Drug: Gemcitabine, Erlotinib
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
    Not yet recruiting - verified May 2012
  • Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

    Condition:   Pancreas, Adenocarcinoma
    Intervention:   Biological: Biological/Vaccine: BC-819
    Sponsors:   BioCancell Therapeutics Israel Ltd.;   BioCancell Therapeutics Israel Ltd.
    Recruiting - verified May 2012
  • Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Efficacy and Safety of Masitinib in Patients With Active Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: masitinib;   Drug: masitinib;   Drug: methotrexate
    Sponsors:   AB Science;   AB Science
    Recruiting - verified May 2011
  • Allogeneic Transplant in HIV Patients (BMT CTN 0903)

    Conditions:   Leukemia;   Lymphoma;   HIV
    Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI);   Drug: Fludarabine;   Drug: Busulfan, Fludarabine, Cyclophosphamide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified March 2012
  • Reduced Intensity Double Umbilical Cord Blood Transplantation

    Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Radiation: Total Body Radiation;   Biological: Cord Blood
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
    Recruiting - verified December 2011
  • A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

    Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
    Interventions:   Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Ambit Biosciences Corporation
    Recruiting - verified September 2011
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

    Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
    Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

    Condition:   Pancreatic Neoplasms
    Interventions:   Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Drug: PF-04136309
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Short Course Radiation Therapy With Proton Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Capecitabine;   Drug: Hydroxychloroquine;   Radiation: Proton Radiation Therapy
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
    Recruiting - verified December 2011
  • High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

    Conditions:   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Radiation: yttrium Y 90 ibritumomab tiuxetan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Biological: rituximab
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

    Conditions:   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Lymphoma;   Neurotoxicity;   Radiation Toxicity
    Interventions:   Biological: rituximab;   Drug: cytarabine;   Drug: methotrexate;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: dexamethasone;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: temsirolimus;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

    Conditions:   Chronic Hepatitis C;   Genotype 1
    Interventions:   Procedure: Educational Intervention;   Other: No Intervention
    Sponsors:   Chronic Liver Disease Foundation;   Chronic Liver Disease Foundation;   Clinical Development Group
    Recruiting - verified February 2012
  • Gemcitabine in Combination With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

    Condition:   Resectable Pancreatic Adenocarcinoma
    Interventions:   Drug: LDE-225;   Drug: Gemcitabine
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Novartis
    Recruiting - verified March 2012
  • Phase 1 Study of Combotox With Cytarabine in Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia (ALL)

    Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Combotox;   Drug: Cytarabine
    Sponsors:   Montefiore Medical Center;   Montefiore Medical Center;   University of Texas Southwestern Medical Center
    Recruiting - verified March 2012
  • Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

    Condition:   Ulcerative Colitis
    Intervention:   Drug: Methotrexate
    Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified March 2012
  • Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Intervention:   Drug: dasatinib
    Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting - verified February 2012
  • A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

    Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
    Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Ambit Biosciences Corporation
    Recruiting - verified May 2012
  • Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

    Conditions:   Leukemia;   Chronic Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Procedure: NK cell infusion:;   Drug: Interleukin-2;   Drug: Anti-Thymocyte Globulin;   Procedure: Allogeneic related Stem Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

    Condition:   Follicular Lymphoma
    Intervention:   Drug: Low dose methotrexate and Bexxar
    Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   GlaxoSmithKline
    Recruiting - verified August 2011
  • Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline;   Pharmaceutical Product Development Clinical Research Organization (CRO)
    Recruiting - verified February 2012
  • BMS-790052 Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

    Condition:   Hepatitis C
    Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Peg-Interferon Alfa-2a;   Drug: Ribavirin
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified December 2011
  • Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Condition:   Metastatic Non-Small Cell Lung Cancer
    Interventions:   Drug: ARQ 197 plus erlotinib;   Drug: Pemetrexed, docetaxel or gemcitabine
    Sponsors:   ArQule;   ArQule
    Recruiting - verified January 2012
  • SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: SOM 230 LAR;   Drug: Gemcitabine
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

    Conditions:   Hematologic Malignancies;   Acute Leukemia;   Myelodysplastic Syndrome (MDS);   Specific Subtypes of Refractory Anemia (RA) or Refractory Anemia With Ringed Sideroblasts(RARS) Subtypes;   Myeloproliferative Disorder (MPD);   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myeloma;   Aplastic Anemia
    Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Hematopoietic stem cell transplantation
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
    Recruiting - verified January 2012
  • Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: FOLFIRI-bevacizumab regimen;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: sorafenib tosylate
    Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: rituximab [MabThera/Rituxan];   Drug: methotrexate
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified April 2012
  • Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

    Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Drug: systemic chemotherapy;   Biological: therapeutic allogeneic lymphocytes
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

    Condition:   Low and Intermediate 1 Risk MDS
    Intervention:   Drug: Lenalidomide and azacitidine combination
    Sponsors:   Rush University Medical Center;   Rush University Medical Center;   Celgene Corporation
    Recruiting - verified June 2011
  • Fluvastatin, Simvastatin to Improve Interferon Sensitivity

    Condition:   Chronic Hepatitis C
    Intervention:   Drug: statin
    Sponsors:   Bader, Ted, M.D.;   Bader, Ted, M.D.
    Not yet recruiting - verified June 2011
  • Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

    Condition:   Rectal Cancer
    Interventions:   Drug: Sorafenib;   Drug: 5-Fluorouracil (5-FU);   Radiation: Radiation
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Bayer
    Recruiting - verified April 2012
  • Decitabine for High-Risk Sickle Cell Disease

    Conditions:   Neutropenia;   Sickle Cell Disease;   Decitabine;   Fetal Hemoglobin
    Intervention:   Drug: Decitabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Cabazitaxel - PF Induction Chemotherapy

    Condition:   Squamous Cell Carcinoma of the Head and Neck
    Interventions:   Drug: Cabazitaxel 10mg/m2;   Drug: Cabazitaxel 12.5mg/m2;   Drug: Experimental: Cabazitaxel 15mg/m2;   Drug: Experimental: Cabazitaxel 17.5mg/m2;   Drug: Cabazitaxel 20mg/m2
    Sponsors:   Mount Sinai School of Medicine;   Krzysztof Misiukiewicz;   Sanofi-Aventis;   Mount Sinai School of Medicine
    Recruiting - verified November 2011
  • Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: BMS-945429 Placebo;   Biological: BMS-945429;   Biological: BMS-945429;   Biological: BMS-945429;   Biological: BMS-945429;   Drug: Methotrexate;   Drug: Methotrexate;   Drug: Methotrexate Placebo;   Drug: Methotrexate;   Drug: Adalimumab Placebo;   Drug: Adalimumab
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified January 2012
  • Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

    Conditions:   Nonsquamous Nonsmall Cell Neoplasm of Lung;   Nonsmall Cell Lung Cancer Stage III
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Radiation: Radiation Therapy;   Drug: Pemetrexed;   Drug: Cisplatin;   Radiation: Radiation Therapy;   Procedure: Lobectomy;   Procedure: Lobectomy
    Sponsors:   Medical University of South Carolina;   Medical University of South Carolina
    Recruiting - verified June 2011
  • Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

    Condition:   Leukemia
    Interventions:   Drug: asparaginase;   Drug: bortezomib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C;   Drug: Inotuzumab Ozogamycin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified April 2012
  • A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

    Conditions:   Neoplasms;   Neoplasm Metastasis;   Pancreatic Cancer
    Interventions:   Drug: LY2157299;   Drug: Gemcitabine;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified April 2012
  • Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: IDX184;   Drug: IDX184
    Sponsors:   Idenix Pharmaceuticals;   Idenix Pharmaceuticals
    Recruiting - verified February 2012
  • PRO#0118: Decitabine Plus Mini Flu-Bu

    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Decitabine plus Fludarabine and Busulfan
    Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
    Recruiting - verified October 2011
  • PRO#1278: Fludarabin and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

    Conditions:   Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (TBI)
    Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
    Recruiting - verified June 2011
  • Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

    Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified May 2012
  • Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Procedure: T-Cell Infusion;   Drug: Rituxan;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: ATG;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Not yet recruiting - verified May 2012
  • Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

    Conditions:   Colon Cancer;   Rectal Cancer
    Intervention:   Drug: Study Arm only (modified FOLFOX6)
    Sponsors:   Brown University;   Debora G. Isdale;   Memorial Hospital of Rhode Island;   Rhode Island Hospital;   The Miriam Hospital
    Recruiting - verified May 2012
  • Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

    Condition:   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Drug: ON 01910.Na;   Drug: Gemcitabine;   Drug: Gemcitabine
    Sponsors:   Onconova Therapeutics, Inc.;   Onconova Therapeutics, Inc.;   Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
    Recruiting - verified March 2012
  • Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Capecitabine;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   University of Pittsburgh;   University of Pittsburgh
    Recruiting - verified August 2011
  • FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

    Condition:   Adenocarcinoma of Pancreas
    Intervention:   Drug: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
    Sponsors:   University of Oklahoma;   University of Oklahoma
    Recruiting - verified February 2012
  • A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

    Condition:   Solid Tumour
    Interventions:   Drug: GDC-0425;   Drug: gemcitabine
    Sponsors:   Genentech;   Genentech
    Recruiting - verified March 2012
  • A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia Subjects ≥ 65 Years of Age

    Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified May 2012
  • Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: secukinumab;   Biological: secukinumab;   Biological: placebo
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

    Conditions:   Advanced or Metastatic Solid Tumors;   Previously Untreated Gastric Cancer
    Interventions:   Drug: E7050;   Drug: cisplatin;   Drug: capecitabine
    Sponsors:   Eisai Inc.;   Eisai Inc.;   PharmaBio Development Inc.
    Recruiting - verified April 2012
  • Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

    Conditions:   Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

    Conditions:   Esophageal Cancer;   Malignant Neoplasm of Cardio-esophageal Junction of Stomach
    Interventions:   Drug: Azacitidine;   Drug: Azacitidine;   Drug: Azacitidine;   Drug: Oxaliplatin;   Drug: Oxaliplatin;   Drug: Epirubicin;   Drug: Epirubicin;   Drug: Capecitabine;   Drug: Capecitabine
    Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
    Recruiting - verified June 2011
  • Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: alvocidib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin;   Drug: mitoxantrone hydrochloride
    Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: azacitidine;   Drug: entinostat;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
    Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)

    Condition:   Acute Myelogenous Leukemia
    Interventions:   Drug: FLAM;   Drug: 7&3
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2012
  • Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

    Conditions:   Breast Cancer;   Metastatic Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Ixabepilone;   Drug: Capecitabine;   Drug: Motesanib
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Susan G. Komen Breast Cancer Foundation;   Amgen
    Not yet recruiting - verified January 2012
  • A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

    Condition:   Chronic Myelomonocytic Leukemia
    Intervention:   Drug: 5-Azacitidine
    Sponsors:   University of Utah;   University of Utah;   Celgene Corporation
    Recruiting - verified January 2012
  • Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

    Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Thiotepa;   Genetic: Hematopoietic stem cell transplantation
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
    Recruiting - verified January 2012
  • An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

    Condition:   Hepatitis C, Chronic
    Intervention:  
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified July 2011
  • Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

    Condition:   Metastatic Urothelial Carcinoma
    Intervention:   Drug: Lenalidomide
    Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   Celgene Corporation
    Recruiting - verified October 2011
  • Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

    Condition:   Leukemia, Myelocytic, Acute
    Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Busulfan and Cyclophosphamide (Bu/Cy);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified March 2012
  • Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: cyclosporine;   Drug: pravastatin sodium;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Procedure: bone marrow aspiration
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation

    Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
    Interventions:   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: plerixafor;   Drug: decitabine
    Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Genzyme
    Recruiting - verified June 2011
  • Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)

    Condition:   Stage III Non-small Cell Lung Cancer
    Intervention:   Drug: Chemotherapy following concurrent Chemoradiotherapy
    Sponsors:   Louisiana State University Health Sciences Center Shreveport;   Syed Jafri
    Recruiting - verified April 2012
  • Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

    Conditions:   Solid Tumors;   Non-Small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Panobinostat, Cisplatin, Pemetrexed
    Sponsors:   University of California, Davis;   University of California, Davis;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

    Condition:   Breast Cancer
    Interventions:   Drug: Gemcitabine and Carboplatin;   Drug: P276-00 along with Gemcitabine and carboplatin
    Sponsors:   Piramal Healthcare Limited;   Piramal Healthcare Limited
    Recruiting - verified January 2012
  • PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
    Interventions:   Drug: FOLFOX regimen;   Drug: carboplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: paclitaxel
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

    Condition:   Myeloma
    Intervention:   Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
    Sponsors:   James Graham Brown Cancer Center;   Geoffry Herzig, MD
    Recruiting - verified April 2012
  • A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

    Condition:   Hepatitis C
    Interventions:   Drug: PegIFN/RBV;   Drug: BI 201335
    Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified May 2012
  • GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

    Condition:   Solid Cancers
    Interventions:   Drug: bevacizumab;   Drug: capecitabine;   Drug: GDC-0980;   Drug: mFOLFOX6
    Sponsors:   Genentech;   Genentech
    Recruiting - verified February 2012
  • A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

    Conditions:   Transitional Cell Carcinoma of Bladder;   Urethra Cancer;   Ureter Cancer;   Malignant Tumor of Renal Pelvis
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine;   Biological: ALT-801
    Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

    Condition:   Anal Cancer
    Interventions:   Drug: Tempol;   Drug: 5-Fluorouracil;   Drug: Mitomycin-C;   Procedure: Radiation Therapy
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Intervention:   Drug: TRC105
    Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.;   Roswell Park Cancer Institute;   Department of Defense
    Recruiting - verified March 2012
  • Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Metformin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: PEG-asparaginase;   Drug: Doxorubicin;   Drug: Intrathecal chemotherapy
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Pediatric Cancer Foundation
    Recruiting - verified April 2012
  • Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome
    Intervention:   Drug: Bortezomib, Tacrolimus, Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
    Recruiting - verified May 2011
  • A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

    Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Panobinostat
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Novartis
    Recruiting - verified November 2011
  • Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

    Conditions:   Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
    Interventions:   Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
    Sponsors:   Cell Therapeutics;   Cell Therapeutics
    Recruiting - verified May 2012
  • Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Talon Therapeutics, Inc
    Not yet recruiting - verified May 2012
  • Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

    Conditions:   Liver Metastases;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
    Interventions:   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: bevacizumab;   Procedure: therapeutic conventional surgery;   Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: irinotecan hydrochloride
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

    Conditions:   Hematologic Malignancies;   Nonmalignant Diseases;   Immunodeficiencies;   Hemoglobinopathies;   Genetic Inborn Errors of Metabolism;   Fanconi's Anemia,;   Thalassemia;   Sickle Cell Disease
    Intervention:  
    Sponsors:   University of California, San Francisco;   University of California, San Francisco;   Thrasher Research Fund
    Recruiting - verified September 2011
  • A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

    Condition:   Solid Tumor
    Intervention:   Drug: Tesetaxel plus capecitabine
    Sponsors:   Genta Incorporated;   Genta Incorporated
    Recruiting - verified March 2012
  • Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

    Condition:   Non-infectious Intermediate and Posterior Uveitis
    Intervention:   Drug: Methotrexate
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Eye Institute (NEI)
    Recruiting - verified October 2011
  • Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

    Conditions:   Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: OC-DC vaccine;   Drug: Bevacizumab;   Drug: cyclophosphamide 300 mg/m2/d for 3 days;   Drug: fludarabine 30 mg/m2/d for 3 days;   Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified June 2011
  • Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Imatinib mesylate
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2012
  • A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

    Conditions:   Locally Advanced Malignant Neoplasm;   Malignant Solid Tumour
    Intervention:   Biological: ALT-836 in combination with gemcitabine
    Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation
    Recruiting - verified September 2011
  • Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: panitumumab;   Drug: Randomization to No Panitumumab
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Amgen
    Recruiting - verified March 2012
  • Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

    Condition:   Non Small Cell Lung Cancer (NSCLC)
    Intervention:   Drug: Bavituximab
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Peregrine Pharmaceuticals
    Recruiting - verified April 2012
  • Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

    Conditions:   Head and Neck Cancer;   Advanced Solid Tumors
    Intervention:   Genetic: Ad/PNP and fludarabine monophosphate
    Sponsors:   PNP Therapeutics, Inc.;   PNP Therapeutics, Inc.
    Recruiting - verified December 2011
  • Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer

    Conditions:   Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Stage II Esophageal Cancer
    Interventions:   Biological: panitumumab;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Radiation: radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: high performance liquid chromatography;   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: pharmacological study;   Other: pharmacogenomic studies
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified July 2011
  • Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

    Condition:   Hepatitis C
    Interventions:   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: Ribavirin (RBV);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor);   Drug: Placebo for Ribavirin (RBV);   Drug: Placebo for Ribavirin (RBV)
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified April 2012
  • A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Entinostat;   Drug: 5-azacitidine
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified April 2012
  • A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Sapacitabine and decitabine;   Drug: Decitabine
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
    Recruiting - verified November 2011
  • A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

    Condition:   HER-2 Gene Amplification
    Interventions:   Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111;   Drug: Lapatinib, Trastuzumab and MM-111;   Drug: Paclitaxel, Trastuzumab and MM-111
    Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
    Recruiting - verified March 2012
  • Study of BKM120 or BEZ235 and Capecitabine in Patients With Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: BMK120;   Drug: Capecitabine;   Drug: BEZ235
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in K-RAS/BRAF Mutant Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer Metastatic
    Interventions:   Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Bayer
    Recruiting - verified April 2012
  • Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Biological: ganitumab;   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
    Interventions:   Radiation: Indium-111 111In anti-CD45 monoclonal antibody BC8 (dosimetric dose); yttrium Y 90 anti-CD45 monoclonal antibody BC8 (therapeutic dose);   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Other: flow cytometry;   Genetic: cytogenetic analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

    Condition:   Resectable Pancreatic Cancer
    Intervention:   Drug: Abraxane plus Gemcitabine
    Sponsors:   Pancreatic Cancer Research Team;   Pancreatic Cancer Research Team;   Celgene Corporation
    Recruiting - verified November 2011
  • A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)

    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
    Sponsors:   Genentech;   Genentech
    Recruiting - verified March 2012
  • Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: BKM120 or Docetaxel;   Drug: BKM120 or Docetaxel or Pemetrexed
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified May 2012
  • Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

    Conditions:   Histologically or Cytologically Confirmed Pancreatic Ca;   Unresectable or Borderline Resectable Pancreatic Ca
    Interventions:   Drug: Gemcitabine;   Procedure: Intra Arterial Catheterization and Embolization;   Device: Indwelling Intraarterial Catheter
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Intervention:   Biological: Panitumumab
    Sponsors:   Women and Infants Hospital of Rhode Island;   Women and Infants Hospital of Rhode Island;   Amgen
    Recruiting - verified March 2012
  • Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer

    Conditions:   Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • GSK1120212 Rollover Study

    Condition:   Cancer
    Interventions:   Drug: GSK1120212;   Drug: Docetaxel + GSK1120212;   Drug: Erlotinib + GSK1120212;   Drug: Pemetrexed + GSK1120212;   Drug: Carboplatin + GSK1120212;   Drug: Nab-paclitaxel + GSK1120212;   Drug: Gemcitabine + GSK1120212;   Drug: Everolimus + GSK1120212
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified April 2012
  • Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

    Condition:   Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

    Conditions:   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Genetic: nucleic acid sequencing;   Procedure: therapeutic conventional surgery
    Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

    Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Sarcoma;   Desmoplastic Small Round Cell Tumor
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Biological: NK-DLI Infusions
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

    Condition:   Lung Cancer, Small Cell
    Interventions:   Drug: pazopanib;   Drug: pemetrexed
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified April 2012
  • Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

    Condition:   Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
    Interventions:   Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm);   Drug: Fluorouracil/cisplatin (control arm)
    Sponsors:   Taiho Pharma USA, Inc.;   Taiho Pharma USA, Inc.
    Recruiting - verified April 2012
  • A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: adalimumab;   Drug: Placebo;   Drug: Placebo;   Drug: methotrexate;   Drug: folate
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified April 2012
  • Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

    Conditions:   Bladder Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
    Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   National Cancer Institute (NCI);   University of Pittsburgh;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Biological: cetuximab;   Drug: capecitabine;   Genetic: mutation analysis;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: nucleic acid sequencing;   Genetic: protein expression analysis;   Genetic: polymerase chain reaction;   Genetic: DNA analysis
    Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

    Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
    Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
    Recruiting - verified February 2012
  • Gemcitabine Pharmacokinetics

    Condition:   Pancreatic Cancer
    Intervention:   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

    Conditions:   Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Primary Peritoneal Neoplasm
    Interventions:   Biological: KHK2866;   Drug: Gemcitabine and Carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin
    Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin Pharma, Inc.
    Recruiting - verified February 2012
  • Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

    Conditions:   Myelodysplastic Syndrome;   Myelofibrosis;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Luitpold Azacitidine;   Drug: Vidaza®
    Sponsors:   Luitpold Pharmaceuticals;   Luitpold Pharmaceuticals
    Recruiting - verified June 2011
  • Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer

    Condition:   Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
    Interventions:   Biological: REOLYSIN;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU)
    Sponsors:   Oncolytics Biotech;   Oncolytics Biotech;   Montefiore Medical Center
    Recruiting - verified December 2011
  • Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

    Condition:   Leukemia
    Interventions:   Drug: Omacetaxine;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   ChemGenex Pharmaceuticals
    Recruiting - verified December 2011
  • Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

    Condition:   CNS Germ Cell Tumor
    Intervention:   Drug: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
    Sponsors:   Children's Hospital Los Angeles;   Children's Hospital Los Angeles
    Recruiting - verified February 2012
  • Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

    Condition:   Metastatic Pancreatic Cancer
    Interventions:   Biological: bavituximab;   Drug: Gemcitabine
    Sponsors:   Peregrine Pharmaceuticals;   Peregrine Pharmaceuticals
    Recruiting - verified May 2012
  • Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: capecitabine;   Drug: vorinostat
    Sponsors:   National Cancer Institute (NCI);   Princess Margaret Hospital, Canada;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

    Condition:   Acute Myelogenous Leukemia (AML)
    Intervention:   Drug: AT-406 in combination with daunorubicin and cytarabine
    Sponsors:   Ascenta Therapeutics;   Ascenta Therapeutics;   The Leukemia and Lymphoma Society
    Recruiting - verified January 2012
  • BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Cixutumumab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Eli Lilly and Company;   Genentech;   ImClone LLC
    Recruiting - verified May 2012
  • Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

    Condition:   Urothelial Carcinoma
    Intervention:   Drug: Gemcitabine and Cisplatin
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2012
  • RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

    Condition:   Bladder Cancer
    Intervention:   Drug: Everolimus and Intravesical Gemcitabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified March 2012
  • Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: fludarabine phosphate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

    Condition:   Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Sorafenib
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bayer;   Onyx Therapeutics, Inc.;   Celgene Corporation
    Recruiting - verified May 2012
  • Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: sorafenib tosylate;   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies

    Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified August 2011
  • Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: sirolimus;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: azacitidine;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: mitoxantrone hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

    Conditions:   Lymphoid Hematological Malignancies;   Umbilical Cord Blood Transplant
    Intervention:   Drug: Cytoxan/TBI/Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified August 2011
  • Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

    Conditions:   Neuroblastoma;   Ewings Sarcoma;   Osteogenic Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma
    Intervention:   Biological: Autologous dendritic cell vaccine with adjuvant
    Sponsors:   Penn State University;   Penn State University;   Solving Kids’ Cancer
    Recruiting - verified January 2012
  • Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: lenalidomide
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified January 2012
  • Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine;   Radiation: Radiation therapy;   Procedure: pancreaticoduodenectomy
    Sponsors:   University of Arkansas;   University of Arkansas
    Recruiting - verified November 2011
  • High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

    Condition:   Myeloma
    Interventions:   Drug: Palifermin;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Combination With Gemcitabine in Advanced Pancreatic Cancer

    Condition:   Pancreatic Neoplasms
    Intervention:   Drug: BAY86-9766+Gemcitabine
    Sponsors:   Bayer;   Bayer
    Recruiting - verified May 2012
  • A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

    Conditions:   Stomach Cancer;   Esophageal Cancer
    Interventions:   Biological: Ramucirumab;   Drug: Placebo;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

    Conditions:   Skin Cancer;   Metastatic Melanoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Other: Gene Transfer
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

    Condition:   Breast Cancer
    Interventions:   Biological: Ramucirumab DP;   Biological: IMC-18F1;   Drug: Capecitabine
    Sponsors:   ImClone LLC;   ImClone LLC
    Recruiting - verified May 2012
  • A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

    Conditions:   Advanced Solid Tumors;   Locally Advanced or Metastatic Breast or Colorectal Cancer
    Intervention:   Drug: tivozanib (AV-951) and capecitabine (Xeloda®)
    Sponsors:   AVEO Pharmaceuticals, Inc.;   AVEO Pharmaceuticals, Inc.
    Recruiting - verified October 2011
  • Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer

    Conditions:   Advanced Solid Tumors;   Metastatic Colorectal Cancer
    Intervention:   Drug: NK012 and 5-FU
    Sponsors:   Nippon Kayaku Co.,Ltd.;   Nippon Kayaku Co.,Ltd.
    Recruiting - verified June 2011
  • Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

    Conditions:   Adenocarcinoma of the Esophagus;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
    Interventions:   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • A Study in Non-Small Cell Lung Cancer

    Condition:   Non-Small-Cell Lung Carcinoma
    Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Cixutumumab
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
    Recruiting - verified April 2012
  • Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Eniluracil;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Capecitabine
    Sponsors:   Adherex Technologies, Inc.;   Adherex Technologies, Inc.
    Recruiting - verified August 2011
  • A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

    Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, B-cell;   Lymphoma, B-cell, Diffuse
    Interventions:   Drug: Inotuzumab ozogamicin;   Drug: Rituximab;   Drug: rituximab + gemcitabine;   Drug: rituximab +bendamustine
    Sponsors:   Pfizer;   Pfizer;   UCB, Inc.
    Recruiting - verified April 2012
  • Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

    Condition:   Metastatic Pancreatic Adenocarcinoma
    Intervention:   Drug: CO-1.01
    Sponsors:   Clovis Oncology, Inc.;   Clovis Oncology, Inc.
    Recruiting - verified March 2012
  • Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Periampullary Adenocarcinoma
    Interventions:   Drug: AZD2171;   Drug: mFOLFOX6
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

    Condition:   Metastatic or Unresectable Solid Tumor Malignancy
    Interventions:   Drug: Capecitabine;   Drug: Hsp90 Inhibitor AUY 922
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Novartis Pharmaceuticals
    Recruiting - verified November 2011
  • Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

    Condition:   Acute Myeloid Leukemia (AML)
    Intervention:   Drug: Panobinostat
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified May 2012
  • FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

    Condition:   Colorectal Cancer
    Interventions:   Drug: Panitumumab;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5-Fluorouracil
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
    Recruiting - verified July 2011
  • GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

    Conditions:   Adenocarcinoma of the Pancreas;   Advanced Solid Tumors;   Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Metastases;   Metastatic Cancer;   Metastatic Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Cancer;   Bone Metastases;   Endocrine Cancer;   Oncology;   Oncology Patients;   Solid Tumors;   Advanced Malignancy
    Interventions:   Drug: AMG 479;   Drug: Placebo;   Drug: AMG 479;   Drug: gemcitabine
    Sponsors:   Amgen;   Amgen;   Takeda Global Research & Development Center, Inc.
    Recruiting - verified May 2012
  • Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes

    Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer
    Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Trimodality Management of T1b Esophageal Cancers

    Condition:   Esophageal Cancer
    Interventions:   Drug: Docetaxel;   Drug: 5-FU;   Radiation: Radiotherapy;   Procedure: Esophagectomy;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine;   Drug: Placebo / Capecitabine
    Sponsors:   Bayer;   Bayer;   Onyx Therapeutics, Inc.
    Recruiting - verified April 2012
  • Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

    Condition:   Advanced Cancers
    Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

    Conditions:   Lung Cancer;   Non Small Cell Lung Carcinoma;   Hypermethylation
    Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Vidaza;   Procedure: Tumor Specimen for Methylation Analysis;   Procedure: Blood Sample for Methylation Analysis;   Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Pemetrexed
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified October 2011
  • Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

    Condition:   Pancreatic Adenocarcinoma
    Intervention:   Drug: Intraperitoneal Gemcitabine
    Sponsors:   Washington Hospital Center;   Washington Hospital Center
    Recruiting - verified April 2012
  • Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

    Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: pralatrexate;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Other: high performance liquid chromatography;   Genetic: polymerase chain reaction;   Genetic: nucleic acid sequencing;   Other: pharmacological study;   Other: pharmacogenomic studies;   Genetic: polymorphism analysis
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Conditions:   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
    Interventions:   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: bevacizumab;   Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

    Conditions:   Rectal Cancer;   Colon Cancer;   Metastasis;   Adenocarcinoma
    Interventions:   Drug: Hydroxychloroquine;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil;   Drug: 5-fluorouracil;   Drug: Bevacizumab
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified May 2012
  • Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

    Condition:   Hematologic Malignancies
    Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus;   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2012
  • PKC412 and 5-Azacytidine

    Condition:   Leukemia
    Interventions:   Drug: 5-azacytidine;   Drug: PKC412
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified January 2012
  • CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

    Condition:   Gastrointestinal Cancer
    Interventions:   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Panitumumab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Amgen
    Recruiting - verified May 2012
  • Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

    Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Fludarabine
    Sponsors:   West Virginia University;   Mehdi Hamadani;   Georgia Health Sciences University
    Recruiting - verified December 2011
  • High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

    Condition:   Lymphoma
    Interventions:   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplantation;   Drug: Palifermin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: LY2127399;   Drug: Placebo every 2 weeks;   Drug: Placebo every 4 weeks
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

    Conditions:   Mucinous Adenocarcinoma of the Rectum;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer
    Interventions:   Drug: paricalcitol;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Drug: fluorouracil
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

    Condition:   Pancreatic Cancer
    Interventions:   Drug: GDC-0449;   Drug: Gemcitabine
    Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Re-expression of ER in Triple Negative Breast Cancers

    Conditions:   Breast Cancer;   Breast Tumors;   Breast Neoplasms
    Intervention:   Drug: Decitabine, LHB589, Tamoxifen
    Sponsors:   Emory University;   Emory University;   Novartis;   Eisai Inc.
    Recruiting - verified May 2012
  • Azacitidine and CAPOX in Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Drug: Azacitidine;   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Azacitidine MTD
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified March 2012
  • Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

    Condition:   Gastrointestinal Cancers
    Interventions:   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Bevacizumab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
    Recruiting - verified March 2012
  • Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

    Condition:   Cancer
    Interventions:   Drug: Trametinib (GSK1120212);   Drug: Docetaxel;   Drug: Erlotinib;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: nab-Paclitaxel;   Drug: Cisplatin
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified April 2012
  • Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Nonlymphocytic Leukemia
    Interventions:   Drug: vosaroxin and cytarabine;   Drug: placebo and cytarabine
    Sponsors:   Sunesis Pharmaceuticals;   Sunesis Pharmaceuticals
    Recruiting - verified April 2012
  • CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

    Conditions:   Esophageal Cancer;   Gastric Cancer
    Interventions:   Drug: bevacizumab;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: capecitabine
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genentech
    Recruiting - verified September 2011
  • Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Fenretinide;   Drug: Cytarabine;   Drug: Methotrexate
    Sponsors:   South Plains Oncology Consortium;   South Plains Oncology Consortium
    Recruiting - verified February 2012
  • A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

    Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Severe Aplastic Anemia;   Refractory Severe Aplastic Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2011
  • Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

    Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Fludarabine;   Drug: Velcade;   Drug: Rituximab
    Sponsors:   Hoosier Oncology Group;   Hoosier Oncology Group;   Genentech;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: Humira (adalimumab);   Drug: Methotrexate (MTX)
    Sponsors:   Abbott;   Abbott
    Recruiting - verified December 2011
  • Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

    Condition:   Early Rheumatoid Arthritis
    Interventions:   Biological: adalimumab;   Drug: methotrexate
    Sponsors:   Abbott;   Abbott
    Recruiting - verified February 2012
  • Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

    Condition:   AML
    Interventions:   Drug: Sirolimus;   Drug: MEC (Mitoxantrone, Etoposide, and Cytarabine)
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   University of Pennsylvania
    Recruiting - verified January 2012
  • Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

    Condition:   Advanced Cancers
    Interventions:   Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Lenalidomide;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified May 2012
  • Tandem Auto-Allo Transplant for Lymphoma

    Conditions:   Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
    Interventions:   Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Drug: Busulfan;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
    Recruiting - verified April 2012
  • Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

    Conditions:   Relapsed Lymphoma;   B Cell Non-Hodgkin Lymphoma;   Refractory Lymphoma;   High Risk Chronic Lymphocytic Leukemia
    Interventions:   Drug: Rituximab;   Biological: Interleukin-2;   Biological: Natural killer cells;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Fludarabine
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

    Condition:   Metastatic Colorectal Cancer
    Intervention:   Drug: FOLFIRI, Avastin, Irinotecan
    Sponsors:   University of Chicago;   University of Chicago;   National Institute for Cancer Research, Italy
    Recruiting - verified June 2011
  • Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

    Conditions:   Bladder Cancer;   Renal Pelvis Cancer;   Ureter Cancer
    Intervention:   Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

    Conditions:   Biliary Tract Cancer;   Gallbladder Cancer
    Interventions:   Drug: Panitumumab;   Drug: oxaliplatin;   Drug: gemcitabine
    Sponsors:   University of Rochester;   University of Rochester;   Amgen
    Recruiting - verified November 2011
  • Open Label Study to Evaluate the Safety, Efficacy, Viral Kinetics, Genetic, Epigenetic, and Proteomic Expression of Weekly Peginterferon Alpha 2a and Ribavirin Therapy for Chronic Hepatitis C in Latino Subjects With and Without HIV Co-infection

    Conditions:   Hepatitis C;   HIV
    Intervention:   Drug: Pegylated interferon with ribavirin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID);   Fundacion de Investigacion de Diego
    Recruiting - verified April 2012
  • Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

    Condition:   Pediatric Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Decitabine;   Drug: Decitabine
    Sponsors:   Eisai Inc.;   Eisai Inc.
    Recruiting - verified April 2012
  • A Study in Second Line Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: Ramucirumab;   Drug: Irinotecan;   Biological: Placebo;   Drug: Folinic Acid;   Drug: 5-Fluorouracil
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
    Recruiting - verified May 2012
  • Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

    Condition:   DOCK8 Deficiency
    Interventions:   Drug: Fludarabine;   Procedure: Allogeneic HSC transplant;   Drug: Cyclophosphamide;   Procedure: Total Body Irradiation (TBI)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Procedure: umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Bortezomib and Midostaurin With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following;   Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: midostaurin, bortezomib,;   Drug: mitoxantrone hydrochloride, etoposide, cytarabine, midostaurin, bortezomib
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center;   Novartis;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified November 2011
  • A Phase II Study Using Short-Term Cultured, CD8+-Enriched Autologous Tumor-infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers

    Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
    Interventions:   Drug: CD8+ young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified September 2010
  • Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: dasatinib;   Drug: Rituximab;   Drug: fludarabine
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
    Recruiting - verified April 2012
  • Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

    Conditions:   Pancreatic Neoplasms;   Pancreatic Cancer
    Interventions:   Drug: Gemcitabine and cisplatin;   Drug: Gemcitabine / Cisplatin
    Sponsors:   Emory University;   Emory University
    Recruiting - verified May 2012
  • Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: azacitidine;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Intervention:   Drug: Vidaza
    Sponsors:   University of Oklahoma;   University of Oklahoma;   Celgene Corporation
    Recruiting - verified March 2012
  • Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Tasocitinib plus Methotrexate;   Drug: Tasocitinib plus placebo methotrexate;   Drug: Placebo tasocitinib plus Methotrexate
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified May 2012
  • Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

    Conditions:   Colorectal Cancer;   Diarrhea;   Neutropenia
    Interventions:   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

    Condition:   Kidney Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: intensity-modulated radiation therapy;   Radiation: total marrow irradiation;   Radiation: tomotherapy;   Drug: tacrolimus;   Drug: sirolimus
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
    Recruiting - verified March 2012
  • A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Biological: 1121B (ramucirumab);   Drug: Pemetrexed;   Drug: Carboplatin (AUC 6);   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Carboplatin (AUC 5)
    Sponsors:   ImClone LLC;   ImClone LLC
    Recruiting - verified December 2011
  • Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: dexamethasone;   Other: DNA methylation analysis;   Other: gene expression analysis;   Other: bone marrow aspiration;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

    Conditions:   Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
    Interventions:   Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Genzyme
    Recruiting - verified November 2011
  • Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

    Condition:   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cetuximab;   Drug: Cetuximab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Radiotherapy (RT);   Other: Chemotherapy
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

    Condition:   Non Squamous Lung Cancer
    Interventions:   Drug: treatment;   Drug: treatment
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified April 2012
  • Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

    Conditions:   Cancer;   Leukemia;   Lymphoma
    Intervention:   Drug: Sirolimus and Methotrexate
    Sponsors:   Children's Hospital of Philadelphia;   Children's Hospital of Philadelphia;   The Leukemia and Lymphoma Society
    Recruiting - verified November 2011
  • Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

    Condition:   Colorectal Cancer
    Interventions:   Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients

    Conditions:   Acute Myeloid Leukemia;   AML
    Intervention:   Drug: Decitabine (Dacogen)
    Sponsors:   University of Utah;   University of Utah;   Eisai Inc.
    Recruiting - verified January 2012
  • Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

    Conditions:   Hepatitis C Infection;   Thrombocytopenia
    Interventions:   Biological: romiplostim;   Drug: ribavirin;   Other: placebo;   Biological: PEG-interferon alfa-2a;   Other: laboratory biomarker analysis
    Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
    Recruiting - verified May 2012
  • A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Conditions:   Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
    Interventions:   Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   University of Virginia;   GlasoSmithKline
    Recruiting - verified April 2012
  • PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

    Conditions:   Cholangiocarcinoma;   Hepatobiliary Neoplasm;   Liver Cancer;   Bile Duct Cancer;   Cancer of Gallbladder
    Interventions:   Procedure: Stereotactic Body Radiotherapy;   Drug: Gemcitabine100 mg/m2;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Capecitabine;   Drug: 5FU
    Sponsors:   Stanford University;   Stanford University
    Recruiting - verified June 2011
  • 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

    Condition:   Leukemia
    Interventions:   Drug: 3 Day Thiarabine;   Drug: 5 Day Thiarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Access Pharmaceuticals, Inc.
    Recruiting - verified February 2012
  • Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Abatacept;   Drug: Methotrexate;   Drug: Abatacept Placebo;   Drug: Methotrexate Placebo
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified February 2012
  • A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

    Condition:   Non-Metastatic Adenocarcinoma of the Rectum
    Interventions:   Procedure: Radiation Therapy;   Drug: Capecitabine;   Drug: AZD6244
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

    Conditions:   Hematologic Malignancy;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia in Blast Crisis;   Anemia, Refractory, With Excess of Blasts;   Chronic Myeloproliferative Disease;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Lymphoma;   Large Cell Non-Hodgkin's Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   High Grade Non-Hodgkin's Lymphoma
    Interventions:   Biological: Treg cells;   Biological: CD3+ Teff cells;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Umbilical cord blood transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified December 2011
  • Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

    Condition:   Multiple Myeloma
    Interventions:   Drug: busulfan, melphalan and fludarabine;   Drug: busulfan, melphalan and fludarabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Otsuka America Pharmaceutical
    Recruiting - verified January 2012
  • Safety Study: Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: combination therapy using decitabine and midostaurin
    Sponsors:   University of Kansas;   University of Kansas;   Novartis
    Recruiting - verified October 2011
  • Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Hydroxychloroquine;   Drug: Gemcitabine
    Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institutes of Health (NIH)
    Recruiting - verified January 2012
  • Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

    Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: bortezomib;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine;   Other: flow cytometry
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
    Recruiting - verified April 2012
  • Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

    Conditions:   Adenocarcinoma of the Esophagus;   Adenocarcinomas of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
    Interventions:   Drug: pralatrexate;   Drug: docetaxel;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Jeffrey Rose;   National Comprehensive Cancer Network
    Recruiting - verified May 2012
  • Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer

    Condition:   Cancer
    Intervention:   Drug: Panitumumab
    Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   Amgen
    Recruiting - verified February 2012
  • Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

    Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
    Interventions:   Drug: azacitidine;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Genetic: protein expression analysis;   Genetic: gene expression analysis;   Genetic: DNA methylation analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Genetic: microarray analysis;   Other: enzyme-linked immunosorbent assay;   Other: liquid chromatography;   Other: mass spectrometry;   Genetic: reverse transcriptase-polymerase chain reaction
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center;   Millennium Pharmaceuticals, Inc.;   Celgene Corporation
    Recruiting - verified November 2011
  • National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

    Condition:   Psoriatic Arthritis
    Interventions:   Drug: Methotrexate;   Drug: Anti-TNF
    Sponsors:   University of Rochester;   University of Rochester;   National Psoriasis Foundation
    Recruiting - verified October 2011
  • HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified December 2011
  • Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

    Condition:   Advanced Cancer
    Interventions:   Drug: Nab-paclitaxel;   Drug: Bevacizumab;   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Other: radiation combined with weekly carboplatin;   Procedure: conservation surgery
    Sponsors:   Southern Illinois University;   Southern Illinois University
    Recruiting - verified March 2012
  • Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Breast Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Biological: Natural killer cells;   Drug: IL-2;   Drug: Methylprednisolone;   Drug: Methylprednisolone;   Drug: Interleukin-2
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

    Condition:   Acute Myeloid Leukemia (AML)
    Interventions:   Drug: Elacytarabine;   Drug: Investigator's Choice
    Sponsors:   Clavis Pharma;   Clavis Pharma
    Recruiting - verified April 2012
  • Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

    Condition:   Bladder Cancer
    Intervention:   Other: external radiation therapy with gemcitabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2012
  • Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

    Condition:   Hemophagocytic Lymphohistiocytosis
    Interventions:   Drug: ATG, rabbit;   Drug: Etoposide;   Drug: Intrathecal Methotrexate;   Drug: hydrocortisone
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Medical Center, Cincinnati
    Recruiting - verified January 2012
  • Simultaneous Integrated Boost (SIB) in Esophageal Cancer

    Condition:   Esophageal Cancer
    Interventions:   Drug: 5-Fluorouracil;   Drug: Docetaxel;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Untreated Adult Acute Myeloid Leukemia;   Myeloproliferative Neoplasm With 10% Blasts or Higher
    Interventions:   Biological: filgrastim;   Drug: clofarabine;   Drug: cytarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL)

    Condition:   Leukemia
    Interventions:   Drug: Bendamustine;   Drug: Fludarabine;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • Study in Head and Neck Cancer

    Condition:   Head and Neck Neoplasms
    Interventions:   Drug: Cetuximab;   Drug: Cisplatin;   Drug: 5 - Fluorouracil
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified February 2012
  • ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Myelodysplasia
    Interventions:   Drug: ABT-348;   Drug: ABT-348;   Drug: ABT-348 and azacitidine
    Sponsors:   Abbott;   Abbott
    Recruiting - verified February 2012
  • Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    Conditions:   Hematopoietic/Lymphoid Cancer;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: midostaurin;   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: bone marrow aspiration;   Other: liquid chromatography;   Other: flow cytometry;   Other: mutation analysis;   Other: pharmacological study;   Other: mass spectrometry;   Other: protein expression analysis
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
    Recruiting - verified March 2012
  • Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

    Condition:   Advanced Solid Tumors
    Interventions:   Dietary Supplement: calcitriol;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified March 2012
  • Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

    Conditions:   Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
    Intervention:   Drug: Bevacizumab, Gemcitabine, docetaxel and valproic acid
    Sponsors:   University of Iowa;   University of Iowa;   Genentech
    Recruiting - verified June 2011
  • Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

    Conditions:   Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
    Interventions:   Drug: CAL-101;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil
    Sponsors:   Gilead Sciences;   Gilead Sciences
    Recruiting - verified April 2012
  • A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

    Condition:   Head and Neck Neoplasms
    Interventions:   Drug: Pemetrexed;   Drug: Cetuximab;   Drug: Carboplatin;   Drug: Cisplatin
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified October 2011
  • Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy

    Condition:   Malignant Mesothelioma
    Interventions:   Drug: pemetrexed disodium;   Other: clinical observation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

    Condition:   Squamous Cell Lung Cancer
    Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus Iniparib
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
    Recruiting - verified March 2012
  • Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
    Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
    Sponsors:   University College, London;   University College, London;   National Cancer Institute (NCI);   Gynecologic Oncology Group
    Recruiting - verified December 2011
  • A Study in Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: cetuximab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: 5-fluorouracil
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Intervention:   Drug: Gemcitabine and Pazopanib
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

    Condition:   Metastatic Pancreatic Cancer
    Intervention:   Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Stand Up To Cancer;   Genentech;   Celgene Corporation
    Recruiting - verified March 2012
  • Immunotherapy Study for Surgically Resected Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
    Sponsors:   NewLink Genetics Corporation;   NewLink Genetics Corporation
    Recruiting - verified May 2012
  • Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: A: Azacitidine (Vidaza);   Drug: B: Conventional Care Regimen
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified March 2012
  • Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

    Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma
    Interventions:   Drug: azacitidine;   Drug: lenalidomide
    Sponsors:   Duke University;   Duke University;   Celgene Corporation
    Recruiting - verified June 2011
  • Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

    Conditions:   Pancreatic Cancer Stage II;   Pancreatic Cancer Stage III
    Interventions:   Drug: Neoadjuvant gemcitabine, capecitabine, and docetaxel;   Drug: Gemcitabine, capecitabine, docetaxel followed by radiotherapy
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: G-CSF, Plerixafor and Azacitidine;   Drug: G-CSF, Plerixafor and Azacitidine;   Drug: G-CSF, Plerixafor and Azacitidine
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

    Condition:   Advanced Solid Tumors
    Interventions:   Drug: veliparib (ABT-888);   Drug: carboplatin;   Drug: gemcitabine
    Sponsors:   Abbott;   Abbott
    Recruiting - verified March 2012
  • A Study in Head and Neck Cancer

    Condition:   Head and Neck Neoplasms
    Interventions:   Drug: Cetuximab;   Drug: Carboplatin;   Drug: 5 - Fluorouracil
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified March 2012
  • Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

    Condition:   Advanced Non-squamous Non-Small Cell Lung Cancer
    Interventions:   Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg;   Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
    Sponsors:   University of Chicago;   University of Chicago;   Genentech
    Recruiting - verified June 2011
  • Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: SAR153191 (REGN88);   Drug: placebo
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   Regeneron Pharmaceuticals
    Recruiting - verified May 2012
  • Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

    Condition:   Carcinoma
    Interventions:   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified December 2011
  • HAI Abraxane With Gemcitabine and Bevacizumab

    Condition:   Advanced Cancers
    Interventions:   Drug: HAI Abraxane;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Filgrastim
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer

    Conditions:   Adenocarcinoma of the Pancreas;   Pancreatic Cancer;   Stage III Pancreatic Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Radiation: hypofractionated radiation therapy;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: protein expression analysis
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone;   Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
    Sponsors:   Pfizer;   Pfizer;   UCB, Inc.
    Recruiting - verified May 2012
  • A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

    Condition:   Advanced Solid Tumors
    Intervention:   Drug: Temsirolimus and capecitabine
    Sponsors:   Georgetown University;   Georgetown University;   Wyeth is now a wholly owned subsidiary of Pfizer
    Recruiting - verified April 2012
  • Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Biological: therapeutic autologous lymphocytes;   Drug: azacitidine;   Drug: lenalidomide
    Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   National Cancer Institute (NCI);   Celgene Corporation
    Recruiting - verified April 2012
  • Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

    Condition:   Systemic Scleroderma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2012
  • RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

    Condition:   Colorectal Cancer
    Interventions:   Drug: RAD011;   Drug: FOLFOX;   Drug: Bevacizumab
    Sponsors:   University of Utah;   University of Utah;   Novartis
    Recruiting - verified January 2012
  • Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine;   Other: clinical observation
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

    Condition:   Non-Small-Cell Lung Cancer
    Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Panitumumab
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
    Recruiting - verified October 2011
  • Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Drug: carboplatin;   Drug: celecoxib;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Other: placebo
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • 5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

    Conditions:   Advanced Cancer;   Solid Tumor;   Lymphoma
    Interventions:   Drug: 5-azacytidine;   Drug: Oxaliplatin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Celgene Corporation
    Recruiting - verified May 2012
  • 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

    Condition:   Leukemia
    Interventions:   Drug: 5-Azacytidine;   Drug: Lenalidomide
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified April 2012
  • Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation;   Amgen
    Recruiting - verified April 2012
  • A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

    Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: Elacytarabine plus idarubicin
    Sponsors:   Clavis Pharma;   Clavis Pharma;   Theradex;   INC Research Limited
    Recruiting - verified February 2012
  • Stem Cell Transplant for Epidermolysis Bullosa

    Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Hematopoietic stem cell transplant;   Procedure: Mesenchymal stem cell transplant;   Radiation: Total body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2012
  • A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

    Condition:   Ovarian Cancer
    Intervention:   Drug: BSI-201
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
    Recruiting - verified June 2011
  • Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

    Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: filgrastim;   Procedure: ex-vivo umbilical cord blood expansion;   Other: DNA analysis;   Procedure: bone marrow aspiration;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: fluorescence in situ hybridization;   Other: laboratory biomarker analysis;   Drug: clofarabine;   Procedure: ex vivo-expanded cord blood progenitor cell infusion
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

    Conditions:   Head and Neck Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity
    Interventions:   Drug: lapatinib ditosylate;   Drug: capecitabine
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified May 2012
  • Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: laboratory biomarker analysis;   Procedure: flow cytometry;   Radiation: total-body irradiation;   Genetic: fluorescence in situ hybridization;   Genetic: western blotting;   Procedure: polymerase chain reaction;   Biological: filgrastim
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Dose Dense MVAC for Muscle Invasive Bladder Cancer

    Conditions:   Muscle Invasive Bladder Cancer;   High Risk Urothelial Carcinoma of the Upper Urinary Tracts
    Intervention:   Drug: single arm dose dense MVAC
    Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center
    Recruiting - verified March 2012
  • Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

    Conditions:   Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

    Conditions:   Pancreatic Cancer;   Ductal Adrenocarcinoma;   Exocrine Pancreatic Cancer
    Intervention:   Drug: PCI-27483
    Sponsors:   Pharmacyclics;   Pharmacyclics
    Recruiting - verified January 2012
  • Azacitidine and Lenalidomide for Acute Myeloid Leukemia

    Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

    Conditions:   Brain Cancer;   Choroid Plexus Tumors
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dactinomycin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Methotrexate;   Drug: Temozolomide;   Drug: Vincristine
    Sponsors:   Tufts Medical Center;   Tufts Medical Center
    Recruiting - verified April 2012
  • Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

    Condition:   Pancreatic Cancer
    Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

    Condition:   Sarcoma
    Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
    Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

    Conditions:   Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

    Condition:   Active Rheumatoid Arthritis
    Intervention:   Drug: SBI-087
    Sponsors:   Pfizer;   Pfizer;   Emergent Product Development Seattle LLC
    Recruiting - verified April 2012
  • Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Genetic: RNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Procedure: allogeneic peripheral blood mononuclear stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

    Condition:   Cholangiocarcinoma
    Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Genentech
    Recruiting - verified December 2011
  • Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: vincristine sulfate;   Other: pharmacological study
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2011
  • Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: XELOX regimen;   Drug: hydroxychloroquine
    Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer

    Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
    Interventions:   Drug: Carboplatin;   Drug: Pemetrexed
    Sponsors:   Montefiore Medical Center;   Montefiore Medical Center
    Recruiting - verified July 2011
  • Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

    Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Decitabine and Bexarotene;   Drug: Decitabine and Bexarotene;   Drug: Decitabine and Bexarotene
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

    Condition:   Metastatic Pancreatic Adenocarcinoma
    Interventions:   Biological: REOLYSIN;   Drug: Gemcitabine
    Sponsors:   Oncolytics Biotech;   Oncolytics Biotech;   University of Texas
    Recruiting - verified May 2011
  • A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

    Condition:   Non-Small Cell Lung Cancer
    Intervention:   Drug: Pemetrexed, Cisplatin, Bevacizumab
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

    Conditions:   Anaplastic Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome
    Interventions:   Drug: rituximab;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: bortezomib;   Drug: vorinostat;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

    Conditions:   Central Nervous System Metastases;   Leptomeningeal Metastases;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
    Interventions:   Drug: methotrexate;   Drug: liposomal cytarabine;   Other: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: Plerixafor
    Sponsors:   Genzyme;   Genzyme
    Recruiting - verified January 2012
  • Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia
    Interventions:   Biological: pretargeted radioimmunotherapy;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Other: pharmacological study;   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

    Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Other: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. CD34+ T-cell depleted peripheral blood stem cell transplant
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Hospital Boston;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Rockefeller University;   Fred Hutchinson Cancer Research Center
    Recruiting - verified November 2011
  • Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Pancreatic Cancer;   Periampullary Adenocarcinoma;   Small Intestine Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: oxaliplatin;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

    Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Interventions:   Drug: Decitabine 5 mg/m2/day;   Drug: Decitabine 7.5mg /m2/day;   Drug: Decitabine 10 mg/m2/day
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

    Conditions:   Pancreatic Cancer;   Periampullary Adenocarcinoma
    Interventions:   Drug: capecitabine;   Drug: vorinostat;   Radiation: Radiotherapy;   Procedure: Surgery to remove tumor
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI);   National Comprehensive Cancer Network
    Recruiting - verified January 2012
  • Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

    Condition:   Bladder Cancer
    Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: mitomycin C
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

    Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
    Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
    Recruiting - verified November 2011
  • Treatment of Older Adults With Acute Lymphoblastic Leukemia

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG-asparaginase;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Imatinib;   Drug: Clofarabine;   Drug: 6 Mercaptopurine
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Enzon Pharmaceuticals, Inc.;   Genzyme
    Recruiting - verified April 2012
  • A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: GDC-0941;   Drug: paclitaxel;   Drug: pemetrexed;   Drug: cisplatin
    Sponsors:   Genentech;   Genentech
    Recruiting - verified November 2011
  • Autologous CD19-specific T Cells Infusion

    Conditions:   Lymphoma;   B-cell Lymphoma
    Interventions:   Procedure: Leukapheresis;   Procedure: Stem Cell Transplant;   Procedure: CD19-specific T Cell Infusion;   Drug: IL-2;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

    Conditions:   Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Drug: Everolimus (RAD001);   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Methotrexate;   Drug: Ara-C (Cytarabine);   Drug: Solu-Medrol;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified November 2011
  • Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

    Condition:   Breast Cancer
    Intervention:   Drug: Capecitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Not yet recruiting - verified May 2012
  • Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Erlotinib;   Drug: capecitabine;   Radiation: Radiation Therapy;   Drug: gemcitabine;   Drug: erlotinib
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Genentech
    Recruiting - verified April 2012
  • Sickle Cell Disease Conditioning for Bone Marrow Transplant

    Conditions:   Bone Marrow Transplantation;   Sickle Cell Disease
    Intervention:   Drug: fludarabine
    Sponsors:   Emory University;   Emory University
    Recruiting - verified November 2011
  • A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

    Conditions:   Cholangiocarcinoma;   Biliary Tract Cancer;   Gallbladder Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Sorafenib
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified March 2012
  • Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

    Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
    Recruiting - verified August 2011
  • Study of Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Advanced Non-Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Bortezomib;   Drug: Fludarabine;   Drug: Melphalan
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified December 2011
  • Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Condition:   Leukemia
    Interventions:   Drug: Vorinostat;   Drug: Azacitidine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Merck
    Recruiting - verified March 2012
  • Combined Haploidentical-Cord Blood Transplantation for Adults and Children

    Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
    Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin;   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections
    Sponsors:   University of Chicago;   University of Chicago
    Recruiting - verified June 2011
  • Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

    Conditions:   Leukemia;   Lymphoma;   Myeloma
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath;   Procedure: Stem Cell Transplant
    Sponsors:   University of Chicago;   University of Chicago
    Recruiting - verified June 2011
  • A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM4)

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: Vaniprevir (600 mg b.i.d.);   Drug: Vaniprevir (300 mg b.i.d.);   Drug: Pegylated interferon (Peg-IFN);   Drug: Ribavirin (RBV)
    Sponsors:   Merck;   Merck
    Recruiting - verified May 2012
  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial

    Condition:   Gastric Cancer
    Interventions:   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Procedure: Gastrectomy and/or metastasectomy
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

    Condition:   Advanced Cancers
    Interventions:   Drug: HAI Oxaliplatin;   Drug: 5-FU;   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Bevacizumab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Drug: Dasatinib, Mitoxantrone, Cytarabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified January 2012
  • Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
    Interventions:   Drug: capecitabine;   Drug: docetaxel;   Drug: fluorouracil;   Drug: oxaliplatin
    Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

    Condition:   Testicular Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Melphalan;   Drug: Carboplatin;   Drug: Mesna;   Drug: Ifosfamide;   Drug: Etoposide;   Procedure: Stem Cell Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

    Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
    Interventions:   Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified March 2012
  • Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

    Condition:   Colon Cancer With Metastases to the Liver
    Interventions:   Device: LC bead loaded with Irinotecan;   Drug: FOLFOX6 and Avastin
    Sponsors:   University of Louisville;   University of Louisville;   Biocompatibles UK Ltd
    Recruiting - verified November 2011
  • An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: PF-02341066;   Drug: Pemetrexed;   Drug: Docetaxel
    Sponsors:   Pfizer;   Pfizer
    Recruiting - verified April 2012
  • Mechanism of Action Study for Psoriasis

    Condition:   Psoriasis
    Interventions:   Drug: Methotrexate;   Drug: Adalimumab (Humira)
    Sponsors:   Tufts Medical Center;   Tufts Medical Center;   Abbott
    Recruiting - verified July 2011
  • Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

    Conditions:   Non-hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Sirolimus;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

    Condition:   Renal Cell Carcinoma
    Interventions:   Drug: Bevacizumab;   Drug: Azacitidine
    Sponsors:   University of Kansas;   University of Kansas;   Celgene Corporation
    Recruiting - verified October 2011
  • Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

    Conditions:   MonoMAC;   Myelodysplastic Syndrome;   Immunodeficiency
    Interventions:   Procedure: Reduced-Intensity Hematopoietic Stem Cell;   Drug: Fludarabine;   Procedure: Total Body Irradiation (TBI);   Drug: Filgrastim;   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Ursodiol
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: FDG-PET;   Drug: Pemetrexed;   Drug: Sirolimus
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

    Conditions:   Renal Cancer;   Kidney Cancer
    Interventions:   Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer

    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
    Interventions:   Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

    Condition:   Adult T-Cell Leukemia (ATL)
    Interventions:   Drug: LMB-2;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: LMB-2, anti-Tac(Fv)-PE38
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

    Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting - verified June 2011
  • Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

    Condition:   Carcinoma, Non-Small-Cell Lung
    Intervention:   Drug: Pemetrexed and temsirolimus
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

    Condition:   Nonmalignant Neoplasm
    Interventions:   Procedure: umbilical cord blood transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Genetic: DNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Biological: anti-thymocyte globulin
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   medac GmbH
    Recruiting - verified April 2012
  • Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic

    Conditions:   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Drug: vorinostat
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

    Condition:   Central Nervous System Lymphoma
    Intervention:   Drug: pemetrexed
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Eli Lilly and Company;   Dana-Farber Cancer Institute
    Recruiting - verified April 2012
  • Xeloda (Capecitabine) and External Beam Radiation

    Condition:   Breast Cancer
    Interventions:   Radiation: Radiation Therapy;   Drug: Capecitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified January 2012
  • MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

    Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: MLN4924;   Drug: MLN4924 and azacitidine
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Interventions:   Drug: Vorinostat;   Device: Carboplatin;   Drug: Gemcitabine
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Merck
    Recruiting - verified February 2012
  • A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

    Conditions:   Stomach Neoplasms;   Esophageal Neoplasms
    Interventions:   Drug: BMS-833923;   Drug: Cisplatin;   Drug: Capecitabine
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Exelixis
    Recruiting - verified June 2011
  • PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

    Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Fever;   Locally Advanced;   Metastatic Colorectal Cancer;   Neutropenia;   Rectal Cancer
    Interventions:   Drug: Pegfilgrastim;   Drug: Placebo
    Sponsors:   Amgen;   Amgen
    Recruiting - verified January 2012
  • Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Infantile Leukemia (Both AML and ALL);   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasms;   Biphenotypic Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Cytarabine;   Drug: Clofarabine
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified December 2011
  • Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: LBH 589;   Drug: Pemetrexed
    Sponsors:   University of Pittsburgh;   University of Pittsburgh;   Novartis Pharmaceuticals
    Recruiting - verified April 2012
  • Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eli Lilly and Company
    Recruiting - verified March 2012
  • Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

    Condition:   Leukemia, Lymphocytic, Acute
    Interventions:   Drug: Methotrexate;   Drug: Vincristine;   Drug: PEG-l-asparaginase;   Drug: Dexamethasone;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

    Conditions:   Biliary Cancer;   Cholangiocarcinoma
    Intervention:   Drug: Gemcitabine, Irinotecan, Panitumumab
    Sponsors:   University of Pennsylvania;   University of Pennsylvania
    Recruiting - verified December 2011
  • Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

    Condition:   Myelodysplastic Syndrome
    Interventions:   Drug: Decitabine;   Drug: Clofarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genzyme
    Recruiting - verified February 2012
  • Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

    Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Rituximab;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Allopurinol
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified May 2012
  • Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin;   Drug: vorinostat;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

    Conditions:   Head and Neck Cancer;   Cancer of Nasopharynx
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: 5-Fluorouracil;   Procedure: Chemoradiation;   Drug: Carboplatin;   Drug: Cisplatin
    Sponsors:   Stanford University;   A. Dimitrios Colevas
    Recruiting - verified October 2011
  • Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Panitumumab;   Drug: Carboplatin;   Drug: Gemcitabine
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen;   Eli Lilly and Company
    Recruiting - verified October 2011
  • Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Radiation: Accelerated Short Course Radiation;   Drug: Capecitabine
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital
    Recruiting - verified October 2011
  • Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

    Conditions:   Sarcoma;   Leiomyosarcoma;   Malignant Fibrous;   Histiocytoma;   Angiosarcoma
    Intervention:   Drug: gemcitabine and docetaxel with bevacizumab
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
    Recruiting - verified February 2012
  • Randomized Allogeneic Azacitidine Study

    Conditions:   Leukemia;   AML;   MDS
    Intervention:   Drug: Azacitidine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: cytarabine;   Drug: decitabine;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011
  • Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: gemcitabine hydrochloride;   Drug: vinorelbine ditartrate
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified March 2012
  • Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Fludarabine;   Procedure: Stem Cell Transplant (SCT)
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Cephalon
    Recruiting - verified April 2012
  • Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

    Condition:   Pancreas Cancer
    Intervention:   Drug: Lapatinib and Capecitabine
    Sponsors:   Georgetown University;   Georgetown University;   GlaxoSmithKline
    Recruiting - verified October 2011
  • Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: ursodiol;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: positron emission tomography (PET)
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Capecitabine and Temozolomide for Neuroendocrine Cancers

    Condition:   Neuroendocrine Tumors
    Intervention:   Drug: Capecitabine and temozolomide
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

    Condition:   Pancreatic Cancer Stage IVA
    Interventions:   Drug: Gemcitabine, docetaxel, and capecitabine;   Radiation: Radiation therapy with gemcitabine
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Intervention:   Drug: Gemcitabine (Gemzar), docetaxel (Taxotere), and capecitabine (Xeloda)
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

    Conditions:   Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: gemcitabine hydrochloride
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Decitabine;   Drug: Rapamycin
    Sponsors:   University of Rochester;   University of Rochester
    Recruiting - verified September 2011
  • Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: treosulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: methotrexate
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified March 2012
  • Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

    Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelocytic, Chronic
    Interventions:   Other: Allogeneic Lymphocytes;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Cyclosporine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2011
  • Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

    Condition:   Pleural Mesothelioma
    Intervention:   Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

    Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
    Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified March 2012
  • Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Responded to Treatment

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: clofarabine;   Drug: cytarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • A Study for Patients With Pancreatic Cancer

    Condition:   Pancreatic Neoplasms
    Interventions:   Drug: LY2603618;   Drug: Gemcitabine
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Neo-Adjuvant FOLFOX for Rectal Carcinoma

    Condition:   Rectal Neoplasms
    Interventions:   Drug: FOLFOX;   Procedure: total mesorectal excision (TME)
    Sponsors:   Beth Israel Medical Center;   Beth Israel Medical Center;   St. Luke's-Roosevelt Hospital Center
    Recruiting - verified January 2012
  • An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

    Condition:   Breast Cancer
    Interventions:   Drug: trastuzumab emtansine;   Drug: lapatinib;   Drug: capecitabine [Xeloda]
    Sponsors:   Genentech;   Genentech
    Recruiting - verified April 2012
  • Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

    Condition:   Myelodysplastic Syndromes
    Intervention:   Drug: Lenalidomide, Decitabine
    Sponsors:   Duke University;   Duke University;   Celgene Corporation
    Recruiting - verified February 2012
  • Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

    Condition:   Acute Myelogenous Leukemia
    Intervention:   Drug: Etoposide, Cytarabine, Busulfan
    Sponsors:   University of California, San Francisco;   University of California, San Francisco
    Recruiting - verified February 2012
  • Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

    Conditions:   Metastatic Breast Cancer;   Metastases, Brain
    Interventions:   Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified April 2012
  • Efficacy of Methotrexate in Myasthenia Gravis

    Condition:   Myasthenia Gravis
    Interventions:   Drug: Methotrexate;   Other: Placebo
    Sponsors:   University of Kansas;   University of Kansas;   Food and Drug Administration (FDA)
    Recruiting - verified March 2012
  • A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

    Condition:   Triple Negative Breast Cancer
    Intervention:   Drug: gemcitabine plus carboplatin plus BSI-201
    Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   Breast Cancer Research Foundation
    Recruiting - verified December 2011
  • Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

    Conditions:   Stem Cell Transplantation;   Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
    Sponsors:   University of California, Davis;   University of California, Davis;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

    Conditions:   Urothelial Cancer;   Muscle-invasive Urothelial Carcinoma
    Interventions:   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: vinblastine;   Drug: cisplatin;   Drug: Pegfilgrastim
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Amgen
    Recruiting - verified February 2012
  • Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

    Conditions:   Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors;   Tumors
    Interventions:   Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
    Sponsors:   Amgen;   Amgen
    Recruiting - verified March 2012
  • A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: 5-FU;   Drug: oxaliplatin;   Drug: leucovorin
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Bristol-Myers Squibb
    Recruiting - verified March 2012
  • Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias

    Condition:   Acute Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cytarabine;   Drug: G-CSF (Filgrastim, Neupogen);   Drug: Idarubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified November 2011
  • Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

    Condition:   Advanced Cancer
    Interventions:   Drug: Capecitabine;   Drug: Doxorubicin;   Drug: Ixabepilone;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Brivanib alaninate
    Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
    Recruiting - verified February 2012
  • Chemotherapeutic Agents in Brain/Breast

    Conditions:   Breast Cancer;   Metastatic Cancer
    Interventions:   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: lapatinib ditosylate;   Drug: paclitaxel;   Drug: vinorelbine ditartrate;   Drug: Trastuzumab
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   Department of Defense;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Meningeal Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Drug: bortezomib;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Genetic: polymerase chain reaction
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: filgrastim;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

    Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Biological: natural killer cell therapy;   Genetic: fluorescence in situ hybridization;   Genetic: cytogenetic analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
    Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Juvenile Idiopathic Arthritis (JIA) Registry

    Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Biological: adalimumab;   Drug: Methotrexate
    Sponsors:   Abbott;   Abbott
    Recruiting - verified April 2012
  • Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

    Conditions:   Stomach Cancer;   Gastric (Stomach) Cancer;   Neoplasm of Cardioesophageal Junction;   Gastrointestinal Stromal Tumor (GIST)
    Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: capecitabine
    Sponsors:   Stanford University;   Pamela L. Kunz;   Genentech
    Recruiting - verified February 2012
  • Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies

    Condition:   Diabetic Macular Edema
    Intervention:   Drug: Methotrexate intravenous 25mg/ml
    Sponsors:   Wake Forest University;   Wake Forest University
    Recruiting - verified November 2011
  • Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

    Condition:   Bladder Cancer
    Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

    Conditions:   Lupus Nephritis;   Lupus Erythematosus, Systemic
    Interventions:   Drug: Abatacept;   Drug: cyclophosphamide;   Drug: azathioprine;   Drug: prednisone;   Drug: abatacept placebo;   Drug: azathioprine placebo
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified November 2011
  • A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer

    Condition:   Recurrent Non Small Cell Lung Cancer
    Intervention:   Drug: Itraconazole
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified August 2011
  • A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

    Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: 5-Azacitidine, Mylotarg
    Sponsors:   University of California, San Diego;   University of California, San Diego;   Celgene Corporation;   Pfizer
    Recruiting - verified February 2012
  • Proton Therapy for Resectable Carcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Intervention:   Radiation: Proton Therapy, Capecitabine, Gemcitabine
    Sponsors:   University of Florida;   University of Florida
    Recruiting - verified May 2012
  • A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Biological: Bevacizumab
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

    Conditions:   Locally Advanced (Unresectable) Pancreatic Cancer;   Metastatic Pancreatic Cancer
    Interventions:   Drug: gemcitabine;   Drug: Erlotinib;   Radiation: low dose fractionated radiotherapy
    Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center
    Recruiting - verified November 2011
  • Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

    Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer

    Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Breast Cancer
    Interventions:   Drug: Azacitidine (Vidaza);   Drug: Nab-paclitaxel (Abraxane)
    Sponsors:   University of South Alabama;   University of South Alabama;   Celgene Corporation
    Recruiting - verified August 2011
  • Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia
    Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2012
  • Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Kanglaite Injection plus gemcitabine;   Drug: Gemcitabine
    Sponsors:   KangLaiTe USA;   KangLaiTe USA
    Recruiting - verified January 2012
  • Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

    Conditions:   Colorectal Cancer;   Colorectal Carcinoma;   Liver Metastases
    Interventions:   Drug: Systemic chemotherapy (FOLFOX);   Device: SIR-Spheres yttrium-90 microspheres;   Drug: Systemic chemotherapy (FOLFOX)
    Sponsors:   Sirtex Medical;   Sirtex Medical
    Recruiting - verified May 2012
  • Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil;   Procedure: computed tomography;   Procedure: positron emission tomography;   Procedure: quality-of-life assessment;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Procedure: double-unit umbilical cord blood transplantation;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Other: immunologic technique
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

    Condition:   Autoimmune Disorder
    Interventions:   Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy

    Condition:   Mesothelioma
    Intervention:   Other: Pemetrexed + Cisplatin or Carboplatin AUC=5 Pleurectomy/decortication (if feasible) Intensity Modulated Radiation Therapy
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Eli Lilly and Company;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses

    Conditions:   Paranasal Sinuses;   Squamous Cell Carcinoma
    Interventions:   Drug: Docetaxel;   Drug: 5-Fluorouracil;   Drug: Cisplatin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Sanofi-Aventis
    Recruiting - verified March 2012
  • Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Drug: Clofarabine
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Genzyme;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

    Condition:   Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Pemetrexed;   Radiation: Radiation therapy
    Sponsors:   University of Pittsburgh;   University of Pittsburgh;   Eli Lilly and Company;   Genentech
    Recruiting - verified April 2012
  • Yttrium Y 90 Ibritumomab Tiuxetan With or Without Rituximab, Combination Chemotherapy, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: carmustine;   Drug: cytarabine;   Drug: etoposide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
    Interventions:   Drug: LBH589;   Drug: Decitabine
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified September 2011
  • A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred

    Conditions:   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Vorinostat (SAHA) and Niacinamide;   Drug: Vorinostat, Niacinamide and Etoposide
    Sponsors:   Columbia University;   Columbia University;   Merck
    Recruiting - verified February 2012
  • Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Thoracic Radiation Therapy (TRT);   Radiation: Thoracic Radiation Therapy (TRT)
    Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
    Recruiting - verified May 2012
  • Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Drug: capecitabine;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic surgical procedure;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Proton Therapy for Unresectable Cancer (CA) of Pancreas

    Condition:   Pancreatic Cancer
    Intervention:   Other: Capecitabine, proton, Gemcitabine
    Sponsors:   University of Florida;   University of Florida
    Recruiting - verified March 2012
  • T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

    Conditions:   Acute Myelogenous Leukemia;   Lymphoid Leukemia;   Chronic Myelogenous Leukemia;   Malignant Lymphoma;   Hodgkin's Disease;   Chronic Lymphocytic Leukemia;   Myeloproliferative Disorder;   Anemia, Aplastic;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Stem cells;   Drug: Campath
    Sponsors:   University of Chicago;   University of Chicago
    Recruiting - verified June 2011
  • Autologous and Allogeneic Transplant for Relapsed Lymphoma

    Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
    Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
    Sponsors:   Columbia University;   Columbia University;   Duke University
    Recruiting - verified January 2012
  • Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

    Conditions:   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Metastatic Cancer
    Interventions:   Biological: therapeutic autologous lymphocytes;   Biological: aldesleukin;   Drug: cyclophosphaide;   Drug: fludarabine phosphate
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide (CTX);   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Methotrexate (MTX);   Drug: Cytarabine;   Drug: G-CSF;   Drug: Mesna;   Drug: Pegylated asparaginase;   Drug: Pegfilgrastim;   Drug: Solumedrol
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

    Conditions:   Burkitt's Lymphoma;   Burkitt'S-like Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Cytarabine;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified December 2011
  • A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

    Conditions:   Osteosarcoma;   Malignant Fibrous Histiocytoma (MFH) of Bone
    Interventions:   Biological: Bevacizumab;   Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Genentech;   National Institutes of Health (NIH)
    Recruiting - verified June 2011
  • Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium;   Drug: docetaxel
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

    Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
    Interventions:   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Merck
    Recruiting - verified April 2012
  • Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Gemcitabine;   Biological: Avastin
    Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Genentech
    Recruiting - verified August 2011
  • Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: etoposide phosphate;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

    Conditions:   MDS;   AML;   Solid Tumors;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
    Interventions:   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine;   Drug: azacitidine
    Sponsors:   Celgene Corporation;   Celgene Corporation
    Recruiting - verified March 2012
  • Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis

    Condition:   Pulmonary Fibrosis
    Interventions:   Drug: N-acetylcysteine (NAC);   Drug: Placebo
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

    Conditions:   Liver Metastases;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: floxuridine;   Genetic: proteomic profiling;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: liquid chromatography;   Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
    Recruiting - verified March 2012
  • A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)

    Condition:   Solid Tumors
    Interventions:   Drug: MK1775;   Drug: gemcitabine;   Drug: cisplatin;   Drug: carboplatin;   Drug: MK1775;   Drug: MK1775;   Drug: MK1775;   Drug: gemcitabine;   Drug: cisplatin;   Drug: carboplatin
    Sponsors:   Merck;   Merck
    Recruiting - verified May 2012
  • Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

    Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute, T-Cell;   Juvenile Myelomonocytic Leukemia Lymphoblastic;   T-cell Lymphoblastic Lymphoma;   Myelodysplastic Syndrome
    Interventions:   Procedure: Haploidentical donor derived natural killer cell infusion;   Drug: Chemotherapy (Cyclophosphamide, Fludarabine, Interleukin-2, Mesna);   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Assisi Foundation
    Recruiting - verified March 2012
  • Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011
  • Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
    Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Baylor College of Medicine
    Recruiting - verified June 2009
  • Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

    Conditions:   Soft Tissue Sarcoma;   Mesothelioma
    Intervention:   Drug: Azacitidine In Combination With Temozolomide
    Sponsors:   Columbia University;   Columbia University;   Schering-Plough;   Celgene Corporation
    Recruiting - verified October 2011
  • Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

    Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
    Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified April 2012
  • Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

    Condition:   Histiocytosis, Langerhans-cell
    Interventions:   Biological: alemtuzumab;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: stem cell transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

    Conditions:   Acute Myeloid Leukemia;   Advanced Myelodysplastic Syndromes
    Intervention:   Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified November 2011
  • Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment

    Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Biological: panitumumab;   Drug: everolimus;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

    Conditions:   Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Drug: capecitabine;   Radiation: intensity-modulated radiation therapy;   Drug: oxaliplatin;   Procedure: pancreatic surgical procedure;   Procedure: therapeutic conventional surgery
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
    Recruiting - verified May 2012
  • Radiation Therapy CDDP With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

    Condition:   Rectal Cancer
    Interventions:   Drug: Cetuximab;   Drug: 5-Fluorouracil;   Radiation: External Beam Pelvis Radiation Therapy
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Bristol-Myers Squibb
    Recruiting - verified February 2012
  • Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

    Conditions:   Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
    Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   Otsuka Pharmaceutical Development & Commercialization, Inc.
    Recruiting - verified February 2012
  • Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Biological: Rabbit ATG;   Drug: Palifermin
    Sponsors:   Indiana University;   Indiana University
    Recruiting - verified January 2012
  • Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

    Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: cytogenetic analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

    Condition:   Metastatic Liver Cancer
    Interventions:   Device: Sir-Spheres;   Drug: Capecitabine
    Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center;   Sirtex Medical
    Recruiting - verified June 2011
  • A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

    Conditions:   Cancer;   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Fludarabine, Cyclophosphamide;   Procedure: Transplantation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2012
  • [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

    Condition:   Prostate Cancer
    Intervention:   Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified May 2012
  • T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant

    Conditions:   Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Myeloproliferative Disorders
    Interventions:   Drug: Ara C;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: TBI;   Biological: Campath-1h;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
    Recruiting - verified April 2012
  • Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

    Condition:   Aplastic Anemia
    Interventions:   Drug: Cytoxan;   Drug: Campath;   Radiation: Total Body Irradiation (TBI);   Drug: FK-506;   Drug: Methotrexate;   Procedure: Stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified May 2012
  • Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma

    Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma
    Interventions:   Biological: rituximab;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Stem Cell Transplant in Patients With Thalassemia

    Condition:   Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: Bone marrow or stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified May 2012
  • Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation

    Conditions:   Leukemia;   Cancer;   Lymphoma
    Interventions:   Drug: Ara-C;   Drug: Cytoxan;   Drug: Mesna;   Radiation: TBI Fraction;   Procedure: Stem Cell Infusion;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified April 2012
  • Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

    Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Biological: alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: cyclosporine;   Procedure: stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified May 2012
  • Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Brain Mets - Capecitabine and WBRT

    Condition:   Breast Cancer
    Interventions:   Drug: sunitinib;   Drug: capecitabine;   Radiation: WBRT
    Sponsors:   Baylor Breast Care Center;   Baylor Breast Care Center
    Recruiting - verified January 2012
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Southwest Oncology Group
    Recruiting - verified May 2012
  • Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases

    Condition:   Colorectal Liver Metastases
    Interventions:   Drug: Drug: 5-FU;   Drug: Drug: Oxaliplatin
    Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

    Conditions:   Renal Cell Carcinoma;   Neoplasm Metastases
    Interventions:   Drug: Gemcitabine;   Drug: Sunitinib
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Pfizer;   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute
    Recruiting - verified March 2012
  • Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

    Condition:   Precancerous Condition
    Interventions:   Biological: alemtuzumab;   Drug: fludarabine phosphate;   Radiation: low dose total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Intensity-Modulated Radiation Therapy, Fludarabine, and Melphalan Followed by a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: intensity-modulated radiation therapy
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL

    Condition:   Chronic Lymphocytic Leukemia
    Intervention:   Drug: lenalidomide, fludarabine and rituximab
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Celgene Corporation;   Genentech
    Recruiting - verified November 2011
  • Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Drug: celecoxib;   Drug: Docetaxel;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

    Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified June 2011
  • Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

    Conditions:   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer
    Interventions:   Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin;   Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Sanofi-Aventis;   Roche/Genetech;   City of Hope National Medical Center;   Piedmont Hospital Research Institute (PHRI);   Medical College of Wisconsin;   Queens Health Network;   Weill Medical College of Cornell University;   Memorial Cancer Institute, Florida;   University of Pittsburgh;   Long Island Jewish Medical Center;   Nebraska Cancer Specialists Methodist Estabrook Cancer Center
    Recruiting - verified January 2012
  • Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   National Cancer Institute (NCI);   Massachusetts General Hospital
    Recruiting - verified April 2008
  • Primary Breast Cancer Occurring Concomitant With Pregnancy

    Conditions:   Breast Cancer;   Pregnancy
    Interventions:   Drug: 5-Fluorouracil;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

    Conditions:   Lymphoma;   Bone Marrow Transplantation
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Allogeneic Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients Previously Treated With Docetaxel

    Conditions:   Prostate Cancer;   Pain
    Interventions:   Drug: Azacitidine;   Drug: Docetaxel;   Drug: Prednisone;   Genetic: Azacitidine induced demethylation of repetitive elements.;   Genetic: GADD45α methylation and expression in prostate cancer tissue;   Genetic: GADD45α methylation in serum DNA
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified March 2012
  • Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Drug: 5-FU;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Leucovorin;   Drug: Oxaliplatin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified December 2011
  • Cord Blood Expansion on Mesenchymal Stem Cells

    Conditions:   Myelodysplastic Syndrome;   Leukemia
    Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders

    Condition:   Sickle Cell Disease
    Interventions:   Biological: G-CSF;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

    Conditions:   Solid Tumor;   Urethral Cancer
    Interventions:   Drug: Bortezomib;   Drug: Gemcitabine;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

    Conditions:   Mantle Cell Lymphoma;   Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2012
  • ALL Adult Consortium Trial: Adult ALL Trial

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Doxorubicin;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Methylprednisone;   Drug: Hydrocortisone Sodium Succinate;   Drug: Dexamethasone;   Drug: 6-MP;   Drug: PEG-Asparaginase;   Drug: Imatinib;   Drug: Etoposide;   Procedure: Radiation Therapy;   Drug: E. coli Asparaginase
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Children's Hospital Boston
    Recruiting - verified August 2011
  • Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus

    Condition:   Mixed Mullerian Tumors of the Uterus
    Interventions:   Drug: Gemcitabine;   Drug: Oxaliplatin;   Radiation: Radiation
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Sanofi-Aventis;   Brigham and Women's Hospital;   Massachusetts General Hospital
    Recruiting - verified June 2011
  • Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia

    Condition:   Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Bone Marrow Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Abraxane and Alimta in Advanced Solid Tumors

    Conditions:   Breast Cancer;   Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: pemetrexed disodium
    Sponsors:   University of California, Davis;   University of California, Davis;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • SCT for Dyskeratosis Congenita or SAA

    Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Stem Cell Transplantation;   Drug: ATG
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

    Conditions:   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Phase II Trial of Pulsed Paclitaxel With Concurrent Thoracic Radiotherapy, and Adjuvant Gemcitabine and Carboplatin in Stage IIIA and IIIB Non-Small Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Taxol (paclitaxel);   Procedure: Radiotherapy;   Drug: Carboplatin;   Drug: Gemcitabine
    Sponsors:   Leo W. Jenkins Cancer Center;   Leo W. Jenkins Cancer Center
    Recruiting - verified January 2012
  • Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

    Conditions:   Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
    Intervention:   Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
    Sponsors:   Duke University;   Duke University;   Hoffmann-La Roche;   Sanofi-Aventis;   Genentech
    Recruiting - verified December 2011
  • Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

    Condition:   Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies

    Condition:   Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Rituximab;   Drug: Bortezomib;   Other: Allogeneic Stem Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis
    Interventions:   Drug: Busulfan;   Drug: Cytarabine;   Drug: Fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

    Conditions:   Leukemia;   Acute Myeloid Leukemia;   AML
    Interventions:   Drug: Cytarabine;   Drug: Idarubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • 2CDA With Rituximab in Hairy Cell Leukemia

    Condition:   Leukemia
    Interventions:   Drug: Cladribine;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
    Recruiting - verified May 2012
  • Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

    Conditions:   Relapsed Acute Leukemia;   Refractory Acute Leukemia
    Intervention:   Drug: Bortezomib with mitoxantrone, etoposide and cytarabine
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2012
  • Stem Cell Transplant in Sickle Cell Disease and Thalassemia

    Conditions:   Sickle Cell Disease;   Beta Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

    Conditions:   Myelodysplastic Syndrome;   Leukemia
    Interventions:   Drug: Thymoglobulin;   Drug: Busulfan;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified March 2012
  • Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    Conditions:   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Paroxysmal Nocturnal Hemoglobinuria;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis
    Interventions:   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified February 2012
  • BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

    Conditions:   Brain and Central Nervous System Tumors;   Breast Cancer;   Cognitive/Functional Effects;   Drug/Agent Toxicity by Tissue/Organ;   Psychosocial Effects of Cancer and Its Treatment
    Interventions:   Biological: trastuzumab;   Drug: carboplatin;   Drug: methotrexate;   Drug: sodium thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

    Conditions:   Acute Lymphoblastic Leukemia;   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Ara-C
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified November 2011
  • Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

    Condition:   Hodgkin's Disease
    Interventions:   Drug: Gemcitabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Antithymocyte Globulin;   Procedure: Allogeneic Stem Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

    Condition:   Lymphoma
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
    Sponsors:   Northwestern University;   Northwestern University;   National Cancer Institute (NCI)
    Recruiting - verified June 2011
  • Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

    Condition:   Nonneoplastic Condition
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • TBI Dose De-escalation for Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: anti-thymocyte globulin (ATG);   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: ex-vivo umbilical cord blood expansion;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: biopsy;   Other: immunologic technique;   Other: diagnostic laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

    Condition:   Neoplasms, Breast
    Intervention:   Drug: lapatinib + capecitabine
    Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
    Recruiting - verified April 2012
  • Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

    Condition:   Colorectal Cancer
    Interventions:   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: conventional surgery;   Radiation: radiation therapy
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine tartrate
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
    Recruiting - verified February 2012
  • Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

    Condition:   Anal Cancer
    Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

    Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011
  • Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

    Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Rituximab&Methotrexate Chemotherapy w/BBBD & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL

    Conditions:   Brain and Central Nervous System Tumors;   Lymphoma
    Interventions:   Drug: Rituxan;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Leucovorin
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

    Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Chiron Corporation
    Recruiting - verified March 2012
  • Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

    Condition:   Colorectal Cancer
    Interventions:   Drug: capecitabine;   Drug: 5-fluorouracil;   Procedure: Surgical Resection;   Radiation: Radiation therapy
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

    Condition:   Childhood Langerhans Cell Histiocytosis
    Interventions:   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: prednisolone;   Drug: vinblastine sulfate
    Sponsors:   National Cancer Institute (NCI);   Histiocyte Society
    Recruiting - verified May 2007
  • Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

    Conditions:   AIDS-Related Primary Central Nervous System Lymphoma;   HIV
    Interventions:   Drug: Methotrexate;   Biological: rituximab;   Procedure: antiviral therapy;   Drug: leucovorin calcium
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer

    Condition:   Rectal Cancer
    Intervention:   Drug: Oxaliplatin, Capecitabine, Celecoxib with Radiation
    Sponsors:   New Mexico Cancer Care Alliance;   New Mexico Cancer Care Alliance
    Recruiting - verified December 2011
  • Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total Body Irradiation (TBI);   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Phenytoin;   Drug: Methotrexate
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

    Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: paricalcitol
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Abbott
    Recruiting - verified January 2012
  • Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

    Condition:   Sarcoma, Soft Tissue
    Intervention:   Drug: ifosfamide and doxorubicin vs gemcitabine and docetaxel
    Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center
    Recruiting - verified February 2012
  • Stem Cell Transplant for Immunologic or Histiocytic Disorders

    Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Fludarabine, melphalan, ATG or Campath
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Stem Cell Transplant for Hemoglobinopathy

    Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
    Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
    Recruiting - verified April 2012
  • Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

    Conditions:   Testicular Cancer;   Germ Cell Neoplasm
    Intervention:   Drug: paclitaxel, gemcitabine, and oxaliplatin
    Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   Sanofi-Aventis
    Recruiting - verified May 2012
  • Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

    Conditions:   Acute Lymphoblastic Leukemia;   Lymphoma, Lymphoblastic
    Interventions:   Drug: Etoposide, cytarabine, vincristine, dexamethasone;   Drug: methotrexate, teniposide, PEG-asparaginase;   Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine;   Drug: L-asparaginase, erwinia asparaginase;   Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy;   Procedure: Hematopoietic Stem Cell Transplant;   Procedure: Natural Killer (NK) Cell Transplant
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified March 2012
  • Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

    Condition:   Sarcoma
    Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
    Recruiting - verified June 2011
  • Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

    Condition:   Kidney Cancer
    Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Drug: sorafenib tosylate
    Sponsors:   National Cancer Institute (NCI);   Weill Medical College of Cornell University;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Radiation: iodine I 131 monoclonal antibody BC8;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Conditions:   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
    Interventions:   Biological: rituximab;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: bone marrow aspiration;   Procedure: peripheral blood stem cell transplantation;   Genetic: polymerase chain reaction;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: immunologic technique;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

    Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
    Recruiting - verified October 2008
  • Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Biological: recombinant interferon alfa;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Procedure: hyperthermia treatment
    Sponsors:   National Cancer Institute (NCI);   The University of Texas Health Science Center, Houston
    Recruiting - verified December 2008
  • Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cisplatin;   Drug: cytarabine;   Drug: dexamethasone;   Drug: gemcitabine hydrochloride;   Other: clinical observation
    Sponsors:   NCIC Clinical Trials Group;   NCIC Clinical Trials Group
    Recruiting - verified May 2012
  • Stem Cell Transplant for Hematologic Diseases

    Condition:   Hematologic Malignancies
    Interventions:   Biological: Campath 1H;   Drug: Fludarabine;   Procedure: Stem Cell Transplant;   Radiation: TBI
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified April 2012
  • Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

    Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia
    Interventions:   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: imatinib mesylate;   Drug: dasatinib;   Drug: nilotinib;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Biological: therapeutic allogeneic lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Genetic: fluorescence in situ hybridization;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

    Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: therapeutic autologous lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Drug: buthionine sulfoximine;   Drug: melphalan;   Procedure: Peripheral blood stem cell infusion;   Other: Filgrastim
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified December 2011

Main Menu
Clinical Trial Categories
Clinical Trial Locations